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ABSTRACT 
Coxiella burnetii is a Gram-negative intracellular pathogen that encodes a 
specialized type IVb secretion system (T4SS) which is essential for intracellular 
replication, Coxiella-containing vacuole (CCV) formation, modulation of apoptosis, and 
effector translocation. To identify T4SS candidate substrates, we used an enhanced 
bioinformatics guided approach. Expression of 234 T4SS candidate substrates as TEM1 
β-lactamase fusions identified 53 substrates that were translocated in a Dot/Icm-
dependent manner. Large scale screens aimed at identifying localization and function 
revealed that several of these substrates traffic to distinct subcellular compartments and 
interfere with crucial host processes. To determine if any of these T4SS substrates are 
necessary for intracellular replication, we isolated 20 clonal T4SS substrate mutants 
using the Himar1 transposon and transposase. Of these, 10 mutants exhibited defects in 
intracellular growth and CCV formation in HeLa and J774A.1 cells, but displayed 
normal growth in axenic culture. Given their confirmed role in intracellular replication 
and CCV formation, we named 5 of these substrates CirA-E (Coxiella effector for 
intracellular replication). To identify the pathways targeted by these crucial substrates, S. 
cerevisiae strains were co-transformed with pYEp13 yeast genomic library and the T4SS 
substrates. Using this approach we identified multiple members of the Rho family of 
GTPases as suppressors of Cbu0041 (CirA) toxicity. Overexpression in mammalian cells 
resulted in cell rounding, detachment, and reduced stress fibers. Collectively, these 
results indicate that C. burnetii encodes a large repertoire of T4SS substrates that play 
integral roles in host cell subversion and CCV formation. 
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CHAPTER I  
INTRODUCTION  
The organism 
Coxiella burnetii, a Gram-negative naturally obligate intracellular pathogen, is 
the etiological agent of Q fever, a zoonotic disease predominately associated with 
domestic livestock. The primary route of transmission occurs via inhalation of 
contaminated aerosols, resulting in an acute, flu-like illness that is typically self-limiting 
and readily resolves without antibiotic treatment. However, in rare instances chronic Q 
fever can develop that results in chronic endocarditis or hepatitis (81). The highly 
infectious nature, environmental stability, and ease of dissemination led to the 
classification of C. burnetii as a category B select agent and in 1999 it became a 
reportable disease by the CDC (64). Q fever is endemic and cases have been reported in 
virtually every region and major country in the world except New Zealand. While less 
than 1,400 cases were reported in the US between 1948 and 1986, the number of 
annually reported cases in the US has drastically increased since 2000. A recent outbreak 
of Q fever in the Netherlands resulted in over 4,000 documented cases with 20% of 
patients requiring hospitalization (105). Based on the incidence in other countries with a 
longer history of aggressive surveillance as well as common misdiagnosis of Q fever as 
the flu, suggests the incidence of this disease in the US may be significantly higher.  
Prior to the development of genetic tools, the only known virulence factor of C. 
burnetii was lipopolysaccharide (71). Virulent phase I organisms, isolated from natural 
sources, express a complete O antigen whereas avirulent phase II organisms, obtained 
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from serial passage through embryonated eggs or tissue culture, express truncated LPS 
that often lacks the terminal O-antigen sugars (37).  
Intracellular lifestyle of C. burnetii  
Following inhalation, C. burnetii is capable of infecting a variety of host cell 
types with the primary respiratory tract target being alveolar macrophages. Binding of 
unknown bacterial ligand to αvβ3 integrin on the phagocytic cell leads to internalization 
by RAC1-dependent phagocytosis, however internalization of only phase I bacteria leads 
to dramatic reorganization of F-actin (69). While the receptor on nonprofessional 
phagocytes is not known, it is clear that invasion requires cytoskeletal rearrangements 
(69). 
Following phagocytic uptake, the bacteria-containing nascent phagosome traffics 
through the default pathway to establish a Coxiella-containing vacuole (CCV) derived 
from the host lysosomal network. Five minutes after uptake, the nascent phagosome 
transitions from an early phagosome to a late phagosome, as evident by recruitment of 
the small GTPases, Rab5 and Rab7, markers of early and late endosomes, respectively 
(88). However, fusion with the lysosome is delayed by 2 hr compared to phagosomes 
containing latex beads which acquire lysosomal markers within five minutes of uptake. 
During this stall the phagosome engages the autophagic pathway as evident by 
decoration of the CCV membrane with light-chain 3 (LC3), a process that requires active 
bacterial protein synthesis (36, 88). Engagement of the autophagic machinery clearly 
benefits C. burnetii infection as induction of autophagy increases the number of infected 
cells and the size of the CCV (36). While the benefit to the pathogen by this initial stall 
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is unclear, it has been proposed that autophagic vesicles may deliver nutrients and 
membrane to the CCV and which could promote the transition from the small cell 
variant (SCV) to the large cell variant (LCV) (36, 88).   
As the CCV matures into a late phagosome, it loses Rab5 but acquires Rab7, 
lysosome associated membrane glycoprotein 1 (LAMP-1), and vacuolar ATPase 
(vATPase). Acquisition of the vATPase serves to pump protons into the phagosome 
lumen, driving the pH from 5.4 to 5 (44). Finally, the CCV fuses with lysosomes, the 
vacuolar pH reduces to pH 4.5, and it acquires cathepsin D, acid phosphatases, and 
hydrolyases (88).  
As the development of the CCV progresses, it can undergo homotypic fusions 
with other CCVs and heterotypic fusions with vesicles derived the autophagic (88), 
endocytic, or secretory (17) compartments. Multiple fusion events result in generation of 
a “spacious” CCV that often occupies the majority of the host cytoplasmic space. 
Generation of this spacious compartment is also dependent on the actin cytoskeleton and 
members of the Rho GTPase family since destabilization of actin or expression of GDP-
locked RhoA  results in formation of tight vacuoles that do not expand (1). Manipulation 
of these host processes is dependent on bacterial protein synthesis (44).  
Surprisingly, expansion of the CCV does not affect host cell viability, suggesting 
C. burnetii prolongs cell viability by prevention of apoptosis and induction of pro-
survival factors. C. burnetii infected cells are protected from staurosporin induced 
apoptosis and exhibit reduced cleavage of caspase-3, -9 and poly (ADP-ribose) 
polymerase (PARP) (112). Furthermore, tumor necrosis factor-α stimulation resulted in 
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reduced PARP cleavage (112). The bacteria also actively inhibit apoptosis by 
modulating the interplay between Beclin-1 and Bcl-2. Whereas Beclin-1 is recruited to 
the CCV and promotes bacterial replication and vacuole development, the number and 
size of the CCV is significantly reduced when Beclin-1 is unable to interact with Bcl-2 
and this interaction is essential for apoptosis inhibition (107). C. burnetii also promotes 
host cell survival by promoting sustained activation of the pro-survival kinases Akt 
(110), Erk1/2 (110), and PKA (62, 63). Inhibition of these signaling cascades with 
pharmacological inhibitors drastically decreased the anti-apoptotic effect associated with 
the bacteria (48). Importantly, modulation of apoptosis through each pathway requires 
active bacterial protein synthesis and maybe mediated by the activity of bacterial 
effector proteins (62, 107, 110, 112). 
Dot/Icm secretion system 
Central to pathogenesis is a specialized type IVb secretion system that is closely 
related to that of Legionella pneumophila. This system was co-discovered by two lab 
groups that identified mutants with reduced intracellular multiplication (icm) (12) and a 
defect in organelle trafficking (dot), resulting in the dual nomenclature of Dot/Icm (10). 
In Legionella this system is composed of 26 components found on two distinct 20 kb 
regions of the chromosome. While the majority of these components lack homology to 
other orfs, 18 share homology to components of the bacterial conjugative DNA transfer 
systems (77). 
In Legionella these components form a multi-protein apparatus that consists of 
several sub-complexes: the core complex, consisting of DotC, DotD, DotF, DotG and 
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DotH, serve to link the bacteria inner and outer membrane and a second complex 
composed of the coupling protein DotL, DotM, DotN, IcmS, IcmW (76, 106). This 
system also encodes an ATPase, DotB, whose activity is required for secretion (76). 
Coxiella encodes 23 of the 26 components, lacking homologs of DotV, IcmR, 
DotJ (92). Functional similarity between the systems was demonstrated by cross-
complementation of Legionella mutants with Coxiella dotB, icmS, icmW, and icmT 
(115), which suggested that Legionella could serve as a surrogate to study Coxiella 
secretion. 
Identification of C. burnetii T4SS substrates 
 Until recently, a lack of genetic tools significantly hindered the ability to study 
T4SS in C. burnetii, necessitating use of L. pneumophila as a surrogate host. However 
the development of an acidified citrate cysteine media (ACCM) (80) for axenic culture 
of the organism,  the development of C. burnetii shuttle vectors (20), and tools for 
random (7) and site-directed mutagenesis (8) have significantly advanced the field and 
allowed for confirmation of substrate secretion in C. burnetii (18, 20, 57, 109, 113). 
Importantly, the isolation of T4SS mutants have verified that, like the Legionella system, 
the Dot/Icm secretion system of Coxiella is essential for intracellular replication, CCV 
formation, effector translocation, and modulation of host apoptosis (6, 8, 18). 
Numerous strategies have been employed to identify bacterial secretion 
substrates from intracellular pathogens such as L. pneumophila. Bacterial-two-hybrid 
(61) and bioinformatic guided approaches (15, 23, 43, 46, 83, 94) have led to the 
identification of over 250 T4SS substrates, representing approximately 10% of the 
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proteome. While significant homology exists between the two secretion systems, only a 
few of the effectors are conserved, which can be attributed to the vast differences 
between the intracellular niches. This suggests that C. burnetii may possess a unique 
repertoire of virulence factors. However, while homolog between the substrates is 
limited, many of the attributes of secretion substrates are similar and the tools used to 
identify Legionella substrates can be employed to identify Coxiella substrates. 
 DotF, a major component of T4SS core complex, was successful used to identify 
8 Legionella T4SS substrates (61). Given the extensive homology between Coxiella and 
Legionella and the successful use of DotF as bait, a bacterial two-hybrid screen was 
employed to identify Coxiella T4SS substrates. Using this approach, 25 orfs were 
identified that were fused in frame with adenylate cyclase, 11 of which were eliminated 
based on their conservation among other Gram-negative bacteria (20). Use of established 
secretion assays such as CyaA and TEM1 translocation assay identified 6 substrates that 
were positive for translocation in both assays, representing a 42.9% (6/14) predictive 
success rate (20). 
Bioinformatics has emerged as a powerful and effective tool for identifying 
potential bacterial effectors. A recent study by Burstein et al. (14) developed a novel 
computational approach that identified specific traits of bacterial effectors that could be 
exploited to identify candidate effector proteins. To identify C. burnetii T4SS substrates, 
we employed a similar strategy to generate a candidate list consisting of C. burnetii orfs 
that are paralogs to L. pneumophila substrates, harbor eukaryotic-like motifs, contain 
PmrA recognition sites (118) or E-block motifs (46).  
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While the intracellular niche occupied by C. burnetii is truly unique, it is possible 
that some of its effectors target the same host proteins as Legionella effectors.  To 
identify paralogs, Chen et al. (20) conducted a genome wide screen using 134 L. 
pneumophila and 9 C. burnetii secretion substrates. After eliminating 12 substrates 
identified in a previous study (83), this approach identified 15 novel orfs that represent 
candidate substrates. 
 Many intracellular pathogens encode a large number of proteins that possess 
eukaryotic-like motifs that functionally mimic or antagonize host cell proteins to drive 
the infection process. Ankyrin-repeat domains comprise a diverse protein family that 
mediate protein-protein or protein-DNA interactions through the formation of a 
molecular scaffold (83). However, this motif is not restricted to eukaryotes, and has been 
found in several intracellular bacteria (60, 83, 84, 111) where it serves diverse functions 
including chromatin remodeling (84) and inhibition of apoptosis (60). In addition to 
ankyrin-repeat proteins, bioinformatic screening of the C. burnetii genome for proteins 
containing tetratricopeptide repeats (TRPs), coiled-coil domains (CCDs), leucine-rich 
repeats (LRRs), GTPase domains, F-boxes, kinases, and phosphatases domains lead to 
the  identification of 24 novel candidate substrates (20). 
 Many virulent bacterial species encode two-component systems as sophisticated 
mechanisms for responding to specific environmental cues by modifying expression of 
virulence genes and regulating bacterial secretion. Using bioinformatics, Zusman et al. 
(118) identified a conserved regulatory element for five C. burnetii dot/icm genes that 
resembles the PmrA response regulator. Furthermore, using the consensus sequence 
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TTAA-N6-TTAA, they identified 35 L. pneumophila and 68 C. burnetii orfs that contain 
this conserved regulatory element. Secretion assays revealed that 3/5 L. pneumophila 
orfs tested were secreted in a Dot/Icm dependent manner, suggesting that PmrA may 
regulate specific actions of type IV secretion and could be used to identify putative 
secretion candidates (118). By modifying this consensus sequence we identified over 
130 orfs (14, Chapter 2). 
 By examining traits (14) and sequences (54) from Legionella secretion 
substrates, two independent studies concluded that there is a biased toward specific 
amino acids in the last 20 residues of the C-terminus, however both studies were unable 
to identify a consensus sequence. By complementing sidCΔ100, a well characterized 
Legionella effector that lacks the C-terminal secretion signal, with codons from over 400 
potential secretion candidates, Huang et al. (46) determined that the C-terminus of many 
Legionella substrates possess an E-block motif, characterized by 3-6 acidic residues in a 
region spanning 6-10 residues. Using the consensus sequences EExxE, ExE, or EEx the 
authors were able to identify 49 new T4SS substrates, suggesting that the presence of an 
E-block motif may be used to identify novel T4SS substrates (46). Using this motif, we 
identified over 50 orfs that represent potential secretion substrates (Chapter 2).  
Characterization of C. burnetii T4SS substrates 
To date, over one hundred novel T4SS substrates have been identified based on 
genomic (18), bacterial two-hybrid (20), or bioinformatics screens (20, 83, 109, 111). 
However, the function of the vast majority of these substrates remains undefined. Many 
of these substrates lack functional domains that serve as predictors of effector function. 
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To circumvent this, many large scale screens aimed at identifying subcellular 
localization and effector function have been employed to preliminarily characterize these 
substrates (13, 14, 73, Chapter 2). 
Like Legionella, some redundancy appears to exist among Coxiella secretion 
substrates as three substrates, AnkG, CaeA, CaeB, act to independently promote host 
cell viability by modulating apoptosis. The ankyrin-repeat containing protein G (AnkG) 
binds the pro-apoptotic protein, p32, to inhibit apoptosis (60). Anti-apoptotic effector B 
(CaeB)  inhibits apoptosis through a mitochondrial pathway whereas the nuclear effector 
CaeA was also noted to block apoptosis, however very limited data to suggest a 
molecular mechanism for this inhibition (52). 
Finally Coxiella vacuolar protein A (CvpA), modulates clathrin-mediated 
vesicular trafficking. CvpA binds directly to AP2 and the clathrin heavy chain, both of 
which play integral roles in Coxiella replication as siRNA depletion of either 
significantly inhibited C. burnetii replication. Importantly, a ΔcvpA was significantly 
impaired in intracellular replication and vacuole development, highlighting the 
importance clathrin-mediated vesicular trafficking in C. burnetii pathogenesis (57). 
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CHAPTER II 
IDENTIFICATION OF C. BURNETII TYPE IV SECRETION SUBSTRATES 
REQUIRED FOR INTRACELLLAR REPLICATION AND COXIELLA-
CONTAINING VACUOLE FORMATION* 
Summary 
 Coxiella burnetii, the etiological agent of acute and chronic Q fever in humans, is 
a naturally intracellular pathogen that directs the formation of an acidic Coxiella-
containing vacuole (CCV) derived from the host lysosomal network. Central to its 
pathogenesis is a specialized Type IVB secretion system (T4SS) that delivers effectors 
essential for intracellular replication and CCV formation. Using a bioinformatics guided 
approach, 234 T4SS candidate substrates were identified. Expression of each candidate 
as a TEM-1 β-lactamase fusion protein led to the identification of 53 substrates that were 
translocated in a Dot/Icm-dependent manner. Ectopic expression in HeLa cells revealed 
that these substrates trafficked to distinct subcellular sites, including the endoplasmic 
reticulum, mitochondrion, and nucleus. Expression in yeast identified several substrates 
that were capable of interfering with yeast growth, suggesting these substrates target 
crucial host processes. To determine if any of these T4SS substrates are necessary for 
intracellular replication, we isolated 20 clonal T4SS substrate mutants using the Himar1 
transposon and transposase. Among these, ten mutants exhibited defects in intracellular  
*Reprinted with permission from “Identification of C. burnetii type IV secretion 
substrates required for intracellular replication and Coxiella-containing vacuole 
formation” by Weber MM, Chen C, Rowin K, Mertens K, Galvan G, Zhi H, Dealing 
CM, Roman VA, Banga S, Tan Y, Luo Z-Q, Samuel JE. 2013. J. Bacteriol. 195:3914–
24., Copyright [2013]  ASM Journals
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growth and CCV formation in HeLa and J774A.1 cells, but displayed normal growth in 
bacteriological medium. Collectively, these results indicate that C. burnetii encodes a 
large repertoire of T4SS substrates that play integral roles in host cell subversion and 
CCV formation, and suggests less redundancy in effector function than found in the 
comparative Legionella Dot/Icm model. 
Introduction  
Coxiella burnetii, a Gram-negative naturally obligate intracellular pathogen, is 
the etiological agent of Q fever, a zoonotic disease predominately associated with 
domestic livestock. This highly infectious organism is usually acquired via inhalation of 
contaminated aerosols where it manifests as an acute, flu-like illness that is typically 
self-limiting and readily resolves without antibiotic treatment. However, in rare but 
serious instances chronic Q fever can develop, which generally presents as endocarditis 
or hepatitis (47).  
 Actin-dependent endocytosis of C. burnetii by macrophages leads to 
internalization in an early endosome and trafficking through the default endocytic 
pathway to ultimately establish an acidic Coxiella-containing vacuole (CCV) derived 
from the host lysosomal network (81). While the nascent CCV readily acquires Rab5 
and Rab7, markers of early and late endosomes respectively, fusion with the lysosome is 
delayed compared to phagosomes harboring latex beads (44). During this initial stall, the 
Coxiella-containing phagosome undergoes repeated fusions with autophagosomes, an 
interaction that is believed to deliver nutrients to the organism (88). Following this 
delay, the phagosome fuses with the lysosome and the bacteria transition from a 
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nonreplicative small-cell variant (SCV) to the replicative large-cell variant (LCV) (21). 
As replication ensues, the Coxiella-containing vacuole expands to ultimately occupy 
most of the host cell cytoplasm and undergoes repeated fusions with autophagosomes, 
endolysosomes and at later time points, vesicles from the early secretory pathway (17, 
88). Establishment of this intracellular niche is dependent on active bacterial protein 
synthesis (45) and requires manipulation of numerous host cell processes. This includes 
induction of autophagy (88), inhibition of apoptosis (60), modification of kinases and 
phosphatases (48, 110), modulation of the host transcriptome (65), and recruitment of 
secretory components (17). 
Intracellular replication and CCV formation is dependent on a type IVB secretion 
system that is homologous to the Dot/Icm system of Legionella pneumophila (6, 18). In 
Legionella, this system is encoded by 27 dot/icm (defect in organelle 
trafficking/intracellular multiplication) genes (10, 66), 18 of which are homologous to 
components of the tra/trb-encoded DNA conjugative machinery (47). Together these 
components form a pilus-like structure that presumably spans across the inner and outer 
bacterial membranes and forms a translocation pore through the Legionella-containing 
vacuole (LCV), allowing delivery of bacterial effector proteins into the host cell cytosol 
(48). The Dot/Icm system of Coxiella consists of 24 of these  Dot/Icm components, 
lacking homologs of IcmR, DotJ, and DotV (92).  
These systems are functionally analogous, as demonstrated by cross-
complementation of Legionella mutants with Coxiella dotB, icmS, icmW, and icmT 
(115). This similarity has successfully allowed researchers to use the genetically 
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tractable L. pneumophila as a surrogate host to identify C. burnetii T4SS substrates (20, 
60, 83, 109). However only a few of the effectors are conserved, which is consistent with 
the different properties of the vacuoles occupied by these two pathogens. Whereas C. 
burnetii thrives in an acidic, autophagosome-like vacuole, L. pneumophila resides in a 
vacuole with a neutral pH derived from the host endoplasmic reticulum (47). 
Additionally, substantial differences in host range exist with Legionella predominately 
associated with protists and Coxiella being associated with a variety of mammalian 
species. To date, approximately 50 T4SS substrates have been identified in C. burnetii  
using bacterial two-hybrid (20), genomic (60), and ORFs with predicted eukaryotic-like 
domains (20, 83, 109, 111) for the ability to serve as Dot/Icm dependent secretion 
substrates. 
 The goal of the current study was to more comprehensively identify C. burnetii 
T4SS substrates using an enhanced bioinformatics-guided approach. The C. burnetii 
genome was screened for ORFs that contained a PmrA regulatory consensus sequence 
within the predicted promoter region (20, 118), E-block motif (46), or were homologs of 
known effectors. Using this approach, we identified 53 T4SS substrates, 46 of which 
have not been previously reported.  Ectopic expression in mammalian cells and 
heterologous expression in yeast revealed that these substrates traffic to distinct 
subcellular compartments and modulate crucial host processes. The use of the Himar1-
mediated random mutagenesis resulted in the generation of 20 clonal T4SS substrate 
mutants, ten of which were defective in intracellular replication and CCV formation. 
Overall the results of this study suggest that C. burnetii encodes a large repertoire of 
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secretion substrates that play integral roles in host cell subversion, intracellular 
replication, CCV formation and suggest less functional redundancy than the comparative 
Legionella model. 
Materials and methods 
 Bacteria and host cell lines: Bacteria used for this study are listed in Table 2.1. 
C. burnetii Nine Mile phase II (NMII), clone 4 (RSA439) was propagated in ACCM-2 
under microaerophilic conditions as previously described (80). When required, 
350µg/ml kanamycin or 5µg/ml chloramphenicol was added. L. pneumophila strains 
Lp02 and Lp03 (dotA-) were maintained on charcoal yeast extract (CYE) agar or ACES-
broth yeast extract (AYE) broth and 5µg/ml chloroamphenicol was added, as needed. 
 HeLa, Hek293T, and J774A.1 cells were cultured in DMEM with 10% FBS. 
THP-1 and U937 cells were propagated in RPMI with 10% FBS. All cell lines were 
maintained at 37°C with 5% CO2.  
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Table 2.1 Bacterial strains used in this study. 
Strains Phenotype or Description References 
C. burnetii   
RSA439  Phase II, Clone 4 (90) 
RSA439 MK1  CBU0012::Tn, Cmr This study 
RSA439 MK2 CBU0041::Tn, Cmr This study 
RSA439 MK3 CBU0344::Tn, Cmr This study 
RSA439 MK4 CBU0372::Tn, Cmr This study 
RSA439 MK5 CBU0388::Tn, Cmr This study 
RSA439 MK6 CBU0425::Tn, Cmr This study 
RSA439 MK8 CBU0937::Tn, Cmr This study 
RSA439 MK9 CBU1198::Tn, Cmr This study 
RSA439 MK10 CBU1457::Tn, Cmr This study 
RSA439 MK11 CBU1556::Tn, Cmr This study 
RSA439 MK12 CBU1569::Tn, Cmr This study 
RSA439 MK13 CBU1636::Tn, Cmr This study 
RSA439 MK14 CBU1639::Tn, Cmr This study 
RSA439 MK15 CBU1665::Tn, Cmr This study 
RSA439 MK16 CBU2007::Tn, Cmr This study 
RSA439 MK17 CBU2013::Tn, Cmr This study 
RSA439 MK18 CBU2016::Tn, Cmr This study 
RSA439 MK19 CBU2052::Tn, Cmr This study 
RSA439 MK20 CBU2059::Tn, Cmr This study 
RSA439 MK21 icmX::Tn, Cmr This study 
L. pneumophila   
Lp02 Philadelphia-1 rpsL hsdR thyA mutant (10) 
Lp03 Lp02 ΔdotA (10) 
E. coli   
DH5α F´(Φ80d(lacZ)M15), recA1, endA1, gyrA96, thi1, hsdR17 (rk-mk+), 
supE44, relA1, deoR, (lacZYA-argF), U169 
Stratagene 
S. cerevisiae   
W303 MATa ura3-I leu2-3,112 his3-11,15 trpl-1 ade2-1 cad-100 rad5-535 (29) 
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Bioinformatics analysis: For bioinformatic prediction of C. burnetii T4SS 
candidate substrates, RSA493 and L. pneumophila Philadelphia 1 genomes were 
acquired from the J. Craig Venter Institute Comprehensive Microbial Resource 
(http://cmr.jcvi.org/cgi-bin/CMR/GenomePage.cgi?org=). T4SS candidate substrates 
were selected based on the presence of one of the following three features: PmrA 
consensus regulatory sequence in promoter region, E block motif, or homolog to 
Legionella effector. 
We recently reported the identification of 126 putative PmrA regulated C. 
burnetii ORF; however, only 35 of these candidate substrates were tested for Dot/Icm 
dependent translocation (20). We included 83 of the untested putative PmrA regulated 
genes in the current study. 
We scanned the last 30 amino acids of all C. burnetii RSA493 encoding proteins 
for enrichment in glutamate, termed E-block motif (46). Using this algorithm, we 
identified 328 ORFs that encoded a similar motif. Among these, 122 ORFs encode 
hypothetical proteins that were retained in the candidate pool. 
Lastly, we scanned the C. burnetii genome for similarity to the newly identified 
70 Legionella effector proteins (117). To accomplish this, we used all-against-all 
searches of C. burnetii RSA 493 proteins using local BLAST-P. This approach resulted 
in the identification of 42 candidates, 29 were excluded based on their predicted function 
or conservation among Gram-negative bacteria 
 Plasmid construction: To examine Dot/Icm-dependent protein translocation in 
C. burnetii, we generated the kanamycin resistant TEM vector, pCC108, by removing 
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the chloroamphenicol resistance marker (CmR) and mCherry from pKM244 (Mertens et 
al., manuscript in prep.) using HindIII digestion and replaced it with a PCR amplified 
pHSP10-EGFP-pCbu1910-KanR selection marker cassette. pCbu1910-Flag tags-TEM1-
BamHI cassette was assembled using SOEing PCR and the resulting cassette was cloned 
into the SacI/SalI sites to generate pCC108. Identified T4SS substrates were cloned into 
the BamHI/SalI site of pCC108 or pCBTEM to generate N-terminal TEM1 fusion 
proteins. 
 For ectopic expression and yeast toxicity experiments, all identified T4SS 
substrates were PCR amplified and cloned into BglII/SalI sites of pEGFPC1 (BD 
Clontech, Mountain View, CA) to generate N-terminal EGFP fusions or BamHI/SalI 
sites of pYesNTA2 (Invitrogen, Carlsbad, CA). For substrates possessing BamHI or SalI 
sites in the target gene, BglII or XhoI was used (Table 2.2).  
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Table 2.2 Plasmids used in this study. 
Plasmid Description References or Source 
pKM225 pMW1650, com1p-TnA7, groESp-mCherry, com1p-cat, CmR Mertens et al. (Manuscript 
In Prep) 
pKM244 pJB908a, groESp-mCherry, com1p-cat, CmR, AmpR Mertens et al. (Manuscript 
In Prep) 
pCBTEM 
pCBTEM-1 
pCBTEM-2 
pCBTEM-3 
pCBTEM-4 
pCBTEM-5 
pCC108 
pXDC61m, groESp-mCherry, com1p-cat, CmR,  
pCBTEM:: Cbu0069 
pCBTEM:: Cbu0113 
pCBTEM:: Cbu0344 
pCBTEM:: Cbu0606 
pCBTEM:: Cbu01576 
pKM244, HSP10p-EGFP, com1p-Flag-TEM, KanR 
(29) 
This study 
This study 
This study 
This study 
This study 
This study 
pCC108-1 pCC108::CBU0080 This study 
pCC108-2 pCC108::CBU0113 This study 
pCC108-3 
pCC108-4 
pCC108-5 
pCC108-6 
pCC108-7 
pCC108::CBU0388 
pCC108::CBU0885 
                            pCC108::CBU1665 
pCC108::CBU1685 
pCC108::CBU1754 
This study 
This study 
This study 
This study 
This study 
pEGFP-C1 C-terminal fusion to EGFP, kanr Clontech 
pEGFP35  pEGFP-C1::CBU0012 This Study 
pEGFP36 pEGFP-C1::CBU0069 This study 
pEGFP37 pEGFP-C1::CBU0080 This study 
pEGFP38 pEGFP-C1::CBU0113 This study 
pEGFP39 pEGFP-C1::CBU0183 This study 
pEGFP40 pEGFP-C1::CBU0201 This study 
pEGFP41 pEGFP-C1::CBU0212 This study 
pEGFP42 pEGFP-C1::CBU0270 This study 
pEGFP43 pEGFP-C1::CBU0295 This study 
pEGFP44 pEGFP-C1::CBU0344 This study 
pEGFP45 pEGFP-C1::CBU0372 This study 
pEGFP46 pEGFP-C1::CBU0375 This study 
pEGFP47 pEGFP-C1::CBU0376 This study 
pEGFP48 pEGFP-C1::CBU0393 This study 
pEGFP49 pEGFP-C1::CBU0425 This study 
pEGFP50 pEGFP-C1::CBU0469 This study 
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Table 2.2 Continued   
Plasmid Description References or Source 
pEGFP52 pEGFP-C1::CBU0590 This study 
pEGFP53 pEGFP-C1::CBU0606 This study 
pEGFP54 pEGFP-C1::CBU0637 This study 
pEGFP55 pEGFP-C1::CBU0665 This study 
pEGFP55 pEGFP-C1::CBU0773 This study 
pEGFP56 pEGFP-C1::CBU0885 This study 
pEGFP57 pEGFP-C1::CBU1079 This study 
pEGFP58 pEGFP-C1::CBU1102 This study 
pEGFP59 pEGFP-C1::CBU1110 This study 
pEGFP60 pEGFP-C1::CBU1150 This study 
pEGFP62 pEGFP-C1::CBU1198 This study 
pEGFP63 pEGFP-C1::CBU1434 This study 
pEGFP64 pEGFP-C1::CBU1525 This study 
pEGFP65 pEGFP-C1::CBU1566 This study 
pEGFP66 pEGFP-C1::CBU1576 This study 
pEGFP67 pEGFP-C1::CBU1594 This study 
pEGFP68 pEGFP-C1::CBU1607 This study 
pEGFP69 pEGFP-C1::CBU1620 This study 
pEGFP71 pEGFP-C1::CBU1639 This study 
pEGFP72 pEGFP-C1::CBU1665 This study 
pEGFP73 pEGFP-C1::CBU1677 This study 
pEGFP74 pEGFP-C1::CBU1685 This study 
pEGFP75 pEGFP-C1::CBU1754 This study 
pEGFP76 pEGFP-C1::CBU1789 This study 
pEGFP77 pEGFP-C1::CBU1790 This study 
pEGFP78 pEGFP-C1::CBU2007 This study 
pEGFP79 pEGFP-C1::CBU2013 This study 
pEGFP80 pEGFP-C1::CBU2016 This study 
pEGFP81 pEGFP-C1::CBU2028 This study 
pEGFP82 pEGFP-C1::CBU2059 This study 
pEGFP83 pEGFP-C1::CBU2064 This study 
pEGFP84 pEGFP-C1::CBU2076 This study 
pEGFP85 pEGFP-C1::CBUA0015 This study 
pEGFP86 pEGFP-C1::CBUA0019 This study 
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Table 2.2 Continued   
Plasmid Description References or Source 
pYES   
pYES1 pYES::CBU0041 This study 
pYES2 pYES::CBU0129 This study 
pYES3 pYES::CBU0175 This study 
pYES4 pYES::CBU0410 This study 
pYES5 pYES::CBU0414 This study 
pYES6 pYES::CBU0794 This study 
pYES7 pYES::CBU0801 This study 
pYES8 pYES::CBU0814 This study 
pYES9 pYES::CBU0881 This study 
pYES10 pYES::CBU0937 This study 
pYES11 pYES::CBU1045 This study 
pYES12 pYES::CBU1217 This study 
pYES13 pYES::CBU1314 This study 
pYES14 pYES::CBU1379 This study 
pYES15 pYES::CBU1406 This study 
pYES16 pYES::CBU1425 This study 
pYES17 pYES::CBU1457 This study 
pYES18 pYES::CBU1460 This study 
pYES19 pYES::CBU1461 This study 
pYES20 pYES::CBU1524 This study 
pYES21 pYES::CBU1543 This study 
pYES22 pYES::CBU1556 This study 
pYES23 pYES::CBU1569 This study 
pYES24 pYES::CBU1599 This study 
pYES25 pYES::CBU1636 This study 
pYES26 pYES::CBU1751 This study 
pYES27 pYES::CBU1769 This study 
pYES28 pYES::CBU1823 This study 
pYES29 pYES::CBU1825 This study 
pYES30 pYES::CBU2052 This study 
pYES31 pYES::CBU0012  This study 
pYES32 pYES::CBU0080 This study 
pYES33 pYES::CBU0113  This study 
pYES34 pYES::CBU0183 This study 
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Table 2.2 Continued   
Plasmid Description References or Source 
pYES35 pYES::CBU0201 This study 
pYES37 pYES::CBU0295  This study 
pYES38 pYES::CBU0344  This study 
pYES39 pYES::CBU0372 This study 
pYES40 pYES::CBU0375  This study 
pYES41 pYES::CBU0376  This study 
pYES42 pYES::CBU0393 This study 
pYES43 pYES::CBU0425 This study 
pYES44 pYES::CBU0469  This study 
pYES45 pYES::CBU0513 This study 
pYES47 pYES::CBU0590  This study 
pYES48 pYES::CBU0606  This study 
pYES49 pYES::CBU0637 This study 
pYES50 pYES::CBU0665 This study 
pYES51 pYES::CBU0773   This study 
pYES52 pYES::CBU0885  This study 
pYES53 pYES::CBU1079   This study 
pYES54 pYES::CBU1102  This study 
pYES55 pYES::CBU1150 This study 
pYES57 pYES::CBU1198 This study 
pYES58 pYES::CBU1434   This study 
pYES59 pYES::CBU1525 This study 
pYES60 pYES::CBU1566   This study 
pYES61 pYES::CBU1576 This study 
pYES62 pYES::CBU1594 This study 
pYES63 pYES::CBU1607  This study 
pYES64 pYES::CBU1620  This study 
pYES66 pYES::CBU1639 This study 
pYES67 pYES::CBU1665  This study 
pYES68 pYES::CBU1677   This study 
pYES69 pYES::CBU1685 This study 
pYES70 pYES::CBU1754 This study 
pYES71 pYES::CBU1789 This study 
pYES72 pYES::CBU2007  This study 
pYES73 pYES::CBU2013 This study 
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Table 2.2 Continued   
Plasmid Description References or Source 
pYES74 pYES::CBU2016  This study 
pYES75 pYES::CBU2028  This study 
pYES77 pYES::CBU2064  This study 
pYES78 pYES::CBU2076   This study 
pYES79 pYES::CBUA0014 This study 
pYES80 pYES::CBUA0015  This study 
pYES81 pYES::CBUA0019  This study 
pYES82 pYES::CBUA0020 This study 
 
 
 
TEM translocation assays: TEM translocation assays for L. pneumophila and 
C. burnetii, in U937 or THP-1 cells, respectively, were conducted as previously 
described (20). L. pneumophila was transformed with pCBTEM and C. burnetii with 
pCC108 or pCBTEM. Individual colonies expressing the β-lactamase fusion protein 
were selected and propagated in AYE or ACCM-2 broth, respectively.  Where needed, 
expression of fusion proteins was induced with 1 mM isopropyl β-D-1 
thiogalactopyranoside (IPTG) for 48 h. Host cells were seeded at 105/ml in 24-well 
plates and were inoculated with a multiplicity of infection (MOI) of 30 and incubated for 
3 h for infection with L. pneumophila or with an MOI of 100 and incubated for 48h for 
C. burnetii. The L. pneumophila or C. burnetii infected cells were loaded with 50 µl 
6XCCF4/AM solution (LiveBLAzer-FRET B/G Loading Kit, Invitrogen) and incubated 
at room temperature for 2 h or 4 h, respectively. The percentage of blue cells was 
quantified using a Nikon A1 equipped with a chroma β-lactamase filter set (Chroma 
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#41031 excitation: 405 nm emission: 435 nm long-pass). For substrates exhibiting 
translocation rates above 10%, approximately 1000 cells were counted; however for 
substrates exhibiting low translocation rates (less than 10%) approximately 5000 cells 
were counted. Results are presented as mean values from triplicate wells from at least 
two independent experiments. 
Ectopic expression in HeLa cells: To determine subcellular localization of C. 
burnetii T4SS substrates, HeLa cells were seeded in 24-well glass bottom dishes at a 
density of 105/ml. Where indicated, cells were infected at an MOI of 100 with mCherry 
expressing C. burnetii-pKM244. At 72 h post infection, infected or uninfected cells were 
transiently transfected with EGFP fusion constructs using Lipofectamine (Invitrogen) 
following the guidelines outlined by the manufacturer. Twenty four hours post-
transfection, cells were fixed with 4% formaldehyde, permeabilized with ice-cold 
methanol, and nuclei were stained with 1X Hoechst. For colocalization analysis, primary 
antibodies were diluted in 1% BSA and used at the following concentrations: 1:250 anti-
CoxIV (GenScript, Piscataway, NJ) and 1:250 anti-Calnexin (GenScript). Primary 
antibodies were detected using 1:1000 Alexa Fluor 555 (Cell Signaling, Boston, MA) 
diluted in 1% BSA. To assess colocalization with autophagosomes, cells were co-
transformed with EGFP-tagged substrates and pmRFP-LC3 (Addgene, Cambridge, MA). 
Fluorescence images were acquired with a Nikon-A1 microscope using the 60X oil 
immersion object and images were processed using NIS-Elements Software. Similar 
results were obtained from at least three independent experiments with at least 100 
transfected cells per experiment. 
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Yeast toxicity assay: To assess toxicity of C. burnetii T4SS substrates in yeast, 
each ORF was cloned into pYesNTA2 as BamHI/SalI PCR fragments, and the resulting 
constructs were transformed into S. cerevisiae strain W303 using a standard 
transformation protocol (33). Transformants were plated on uracil dropout media, 
supplemented with glucose, and incubated for 72 h at 30°C. Five colonies from each 
transformation were expanded and toxicity was assessed by serially diluting and spotting 
onto the appropriate dropout media (95). Toxicity results were determined from at least 
three independent experiments. 
Secreted embryonic alkaline phosphatase (SEAP) assay: To identify T4SS 
substrates that disrupt the secretory pathway, Hek293T cells were co-transformed with 
pSEAP and pEGFP constructs expressing the T4SS substrates. Twenty-four hours post-
transfection, cells were washed with 1X phosphate-buffered saline (PBS) and incubated 
for an additional 8 h. Following the allotted incubation period, the culture supernatant 
was collected to calculate the extracellular SEAP. For determination of intracellular 
SEAP, cells were lysed (114) and fractions measured for alkaline phosphatase activity 
using the Phospha-Light System (Invitrogen) as described by the manufacturer. Results 
were tabulated from at least 2 independent experiments with at least 3 replicates per 
experiment. 
Generation of C. burnetii transposon mutants: C. burnetii, axenically cultured 
in ACCM-2, was washed twice and resuspended in destilled water to an approximate 
concentration of 109/ml. Bacteial cells were mixed with 1 µg of pKM225 plasmid DNA 
and electroporation was performed as previously described (80). After 7 d, individual 
 25 
 
colonies were picked and expanded in ACCM-2. Genomic DNA was isolated for rescue 
cloning using GenElute Bacterial Genomic DNA Kit (Sigma, St. Louis, MO). Purified 
DNA was digested with HindIII (New England Biolabs, Ipswich, MA), ligated with T4 
DNA ligase (New England Biolabs), and transformed into chemically competent E. coli 
DH5α. To determine genomic insertion site of Himar1 transposon, three colonies per 
transformation were sequenced using ColE1-R (5’-CTTTCCTGCACTAGATCCCC-3’) 
and CatF (5’-GTACTGCGATGAGTGGCAG-3’).  
Growth curve analysis of T4SS substrate mutants: For growth curve 
comparison of C. burnetii T4SS substrate mutants, the concentration of C. burnetii 
strains axenically cultured in ACCM-2 was determined using qPCR with IS1111gene 
specific primers (51). To first verify that mutants had comparable growth rates in axenic 
culture, curves in ACCM-2 were conducted by inoculating 20 ml ACCM-2 with 106/ml 
of RSA439, RSA439 icmX::Tn, or RSA439 specific T4SS substrate mutants. At 1 d, 4 d, 
and 7 d post-inoculation, 1 ml of culture was removed, pelleted, and resuspended in 200 
µl DNA lysis solution with 10 µl of 20 mg/ml proteinase K (13). For cell culture 
comparison, J774A.1 or HeLa cells were seeded in 24-well plates to a density of 105/ml. 
Cells were infected at an MOI of 50 with C. burnetii (RSA439), RSA439 icmX::Tn, or 
RSA439 specific T4SS substrate mutants in triplicate. Four hours post-infection, cells 
were washed twice with 1X PBS to remove uninternalized bacteria, fresh media was 
added to each well, and cultures were incubated at 37°C with 5% CO2. At 1 d, 4 d, and 7 
d, cells were harvested using trypsinization (HeLa) or scraped (J774A.1), and 
resuspended in 200 µl DNA lysis solution with 10 µl of 20 mg/ml proteinase K (13). 
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DNA was isolated from the infected cells and ACCM-2 cultures using High Pure PCR 
Template Prep Kit (Roche Applied Sciences, Indianapolis, IN), and purified DNA was 
quantified using qPCR with TaqMan and primers specific for IS1111 (51). At least three 
independent growth curves for axenic and cell culture were conducted with at least three 
samples per experiment.  
Coinfection: For coinfection experiments, HeLa cells were seeded at a density of 
105/ml onto glass bottom 24-well plates. Cells were infected at an MOI of 100 with 
either wild-type RSA439, specific T4SS substrate mutants, or coinfected with wild-type 
and mutant strains with 1:1 ratio. Four hours post-infection, non-internalized bacteria 
were removed by washing twice with 1X PBS and fresh culture media was added. 
Cultures were propagated for an additional 7 d. Following infection, cells were washed, 
fixed with 4% formaldehyde, and DNA was stained with 1X Hoechst. Fluorescence 
images were acquired with a Nikon-A1 microscope using the 60X oil immersion object 
and images were processed using NIS-Elements Software. Similar results were obtained 
from three independent experiments with at least 50 infected cells per experiment. 
Results 
 Identification of novel C. burnetii T4SS substrates by bioinformatics screen: 
In silicon analyses have succeeded in the prediction of putative secretion substrates in 
bacterial pathogens (14, 20, 46). The use of these computational tools allows one to 
narrow down the number of candidates to experimentally manageable levels. In the 
current study, we have expanded the number of C. burnetii type IV substrates using 
 27 
 
three new parameters: consensus promoter element in PmrA regulation (20, 118), an E- 
block motif (46), and homology to known effectors (117).   
The two component regulatory system PmrA/B regulates several dot/icm genes 
and genes encoding T4SS substrates (118). A recent study revealed that 35 L. 
pneumophila and 68 C. burnetii ORFs contain the PmrA regulatory elements TTAA-N6-
TTAA (118).  In L. pneumophila some of these ORFs code for bona fide Dot/Icm 
substrates, suggesting the usefulness of this prediction. Using 5 dot/icm genes (icmD, 
icmQ, icmV, icmW, and dotD) and several confirmed Coxiella secretion substrates 
(including Cbu1751, AnkB, AnkJ, AnkM), we identified a consensus sequence 
(TTAATATTTTCTTAAGGTTTXTGXGXTAXAAT) (Table 2.3) distinct from that 
reported by Zusman et al. (118). A genome-wide search with this element allowed us to 
obtain 126 candidates, 35 of which have been previously tested (20), and the remaining 
83 (Table 2.3) were tested in the current study. 
 
 
 
 
 
 
 
 
 
 28 
 
Table 2.3 Predicted PmrA regulated ORFs. 
ID 5' End Putative PmrA binding site 3' End Strand Distance of predicted 
binding site to ATG 
CBU0013 13016 TTAAGGTAACTTTAATATTTCTTGGTTAA--ACT 12985 - 29 
CBU0021 18235 TTAATATTTCCTTAACCTAATGAAGTTATT--CT 18266 + 71 
CBU0023 22399 TTAATTTTATCTTAAGATAAGGAAATCTTT-ACT 22367 - 48 
CBU0051 49435 CTCATACTTCCTTAAGGTTTTTTGGAGAT--ACT 49404 - 72 
CBU0069 63320 CTAAGATTATCTTAATTTTAACTTGATAGC-A-T 63351 + 31 
CBU0077 71460 TTAAAATTAAATTAA--TCAATTAATATTGACCT 71491 + 82 
CBU0084 75607 TTAATATTATCTTAAGGTTATTGGGTTATT-C-T 75638 + 0 
CBU0119 111571 TTAAGAAATCTTTAATCTCGCAGTGGTATG-C-T 111540 - 79 
CBU0144 131010 TTAAGTTTGTTTTAATATCGATGTGTCAA--GAT 131041 + 38 
CBU0183 172128 TTAAGAGTATTTTAAGTTTATGCAGATAT--AAT 172159 + 104 
CBU0201 190143 TTAATATTATTTTTA-ATCTTACCTTTAAAAAAT 190111 - 70 
CBU0213 197619 TTAAGATTGAATTAATTTTTGGATATTAC--TTT 197588 - 28 
CBU0215 200426 TTAACAGAAAATTAA--TTTTAGGGATTTCACCT 200395 - 136 
CBU0273 245187 TTAATATTATTTTAACCTTTCGTCCCTAAA-A-T 245156 - 32 
CBU0326 293301 TTAAGAAAATCTTAAATTTTATCGATGATT--CA 293270 - 52 
CBU0343 310482 TTCATATTCACTTAATCTTATTGTAGTAAC-T-T 310513 + 88 
CBU0355 322015 CTAAGATTCTCTTAATCTCATTACAGAATGA--T 322046 + 31 
CBU0361 327063 TTAAGAAAAACTTAAGGAAGAATAGAAAGT--TT 327032 - 106 
CBU0388 348481 TTAATATTCCCCTAAGCTTTATTCGTTACA-C-T 348512 + 72 
CBU0393 357811 TTAATAAAGGTTTAATGTTTTAGAGGTATT-C-T 357780 - 47 
CBU0436 388876 TTAATATTTAATTAAGTTTATTTGTTTAGA-C-T 388845 - 94 
CBU0505 445857 TTAATATTCCCTTAAGTTTTAAGCTTTATA-A-T 445826 - 44 
CBU0600 547351 TTAACTTTACCTTAACAAAACCTGATTAT--ACT 547382 + 35 
CBU0619 565992 TTAATCTTTTCTTAAGGTTTTTGGCTTATA-C-T 565961 - 141 
CBU0625 569123 TTAAGAATTCCTTAATAAATGAATGATAAG-A-T 569154 + 127 
CBU0637 586648 TTAATTTTTACTTAATTTTT-TAATCGACT-TCT 586617 - 123 
CBU0665 606974 TTAATATTTTCTTAATACCGCGATGGTATT-C-T 607005 + 13 
CBU0690 636458 TGAACATGATTTTAA-ATCTTATGGTGTTATGCT 636490 + 82 
CBU0790 737321 TTAATAATTCCCTAATTTCTCAGTGTTATC-C-T 737352 + 83 
CBU0860 816692 TTAATAAATCATTAATATTGTTGTTGGATA-A-T 816723 + 46 
CBU0978 930285 TTAAGCTTTTTTTAATAATAAAATGTTAG--ACT 930316 + 34 
CBU0992 940945 TTAAGATTTTCCTAAGGGTTATGAAGTACT-A-T 940914 - 35 
CBU1017 962048 TTAATTTTATTTTTA--TCTTATTGAT-TTTATT 962078 + 158 
CBU1033 975307 TTAAGAGTTCTTTAAGGTTCGCCCGCTAC--ACT 975338 + 165 
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ID 5' End Putative PmrA binding site 3' End Strand Distance of predicted 
binding site to ATG 
CBU1059 1005087 TTTAGATTATTTTAATTTAAAAAGTTTAG--AGG 1005056 - 147 
CBU1098 1047078 TTAATAAATTCTTAAGATTAAGCTGTTATT-C-T 1047047 - 39 
CBU1103 1051114 TTAATATTCTCTTAAGGTTGATGAGGTAGA-T-T 1051083 - 30 
CBU1110 1056911 TTAATGAAGCTTTAACAATAGAGCGATAT--ACT 1056880 - 23 
CBU1114 1059926 TTCATACTTTTTTAAGCAAACGTTGATAT--CCT 1059895 - 37 
CBU1167 1110630 TTAATATTCTCTTAATAGCTTCATCCAATAA--T 1110599 - 72 
CBU1178 1119864 TTAAAATTTCTTTAATAAACTTCTACTAA--ACT 1119895 + 117 
CBU1198 1142178 TTAAGGCTACGTTAAGTTGAAGGGAGTAA--GAT 1142209 + 44 
CBU1213 1157000 TTAAGATTGATTTAATGTCTGGCGGTTAG--AAT 1157031 + 36 
CBU1216 1161120 TTAATTTTATTTTAATTTATTTCGGATAC--ACT 1161089 - 33 
CBU1226 1176853 TTAATTTTGCTTTAA--ATGCAAGCATTTTTATT 1176822 - 41 
CBU1252 1204114 TTAACGGTAATTTAAGGTTTCTTTTCTAAA-A-T 1204083 - 21 
CBU1253 1204021 TTCAGGTTCACTTAAGTTTAAAAGGTTAA--TTT 1204052 + 235 
CBU1288 1242627 TTAACTTTCTTCTAAGAAAAGACTGTTAT--AGT 1242596 - 44 
CBU1291 1245983 TTAATGGAAACTTAAGCTTTCTTCATTACA-A-T 1246014 + 41 
CBU1368 1318196 TTAATATTTTCTTAATTCCAATTCAGTGTGC--A 1318165 - 94 
CBU1369 1318222 TTAAGCGTAATTTAATATTATGCCCTTAT--AAT 1318253 + 17 
CBU1370 1320557 TTAATTTTTTCATAATGTAGGAATTATAT--ACT 1320526 - 51 
CBU1387 1336989 TTCATATAGCCTTAA--TATGGTTACTGTAAAAT 1337020 + 48 
CBU1409 1359599 TTAAGGTTAACCTAAGCTTGAGTTGTTAGA-A-T 1359630 + 133 
CBU1420 1369171 CTAATATTCCCTTCAGTTTATATTGATAAC-A-T 1369202 + 17 
CBU1523 1471228 TTAAGATTAATTTAC--TCTTGTTATTATTTACA 1471259 + 88 
CBU1530 1481188 TTAATATATTTTTAAGTTTCATACATTAAC-A-T 1481157 - 36 
CBU1535 1484881 TTAAGATTTGTTTAAGCAGGCTGCCCTAT--ACT 1484850 - 45 
CBU1564 1512170 ATCAGATTCCGTTAATAATTCGGCAGTAT--ACT 1512139 - 43 
CBU1576 1522991 TTCATATTTCTTTAATTTTTCAGCGCTATC-A-T 1523022 + 43 
CBU1611 1555499 TTAATATTTTATTAAGTTTATCGATTTATA-G-T 1555468 - 48 
CBU1618 1557905 TTAATATTAAATTAATATTAAGAAAT-AGA-A-T 1557935 + 101 
CBU1624 1563565 TTAATATTTCCTTAAGGTAAGGAAGGTATA--GT 1563534 - 41 
CBU1639 1579897 TTAATTTTGCTTTAAGTTTAACGCGCTAAC-A-T 1579866 - 58 
CBU1649 1589543 TTAATACTGTCTTAAGGAAGTGGTGCTAGC-A-T 1589512 - 42 
CBU1650 1589620 TTAATATTTCGTTAAGGTTAGTGGGCTATT-C-T 1589651 + 48 
CBU1685 1616231 TTAATTTTTCTTTAA--TTAATTTTAATAATATT 1616262 + 18 
CBU1701 1634450 CTAATATTCCCTTAACTTCCTTCTGGTAGG-A-T 1634481 + 33 
Table 2.3 Continued 
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ID 5' End Putative PmrA binding site 3' End Strand Distance of predicted 
binding site to ATG 
CBU1757 1688680 TCAAGACTTAATTAA--TTTATTTTATTTATATG 1688649 - 39 
CBU1775 1705606 CTAAGGTTAGTTTAATCTTGCTAAGGTAA--TAT 1705637 + 65 
CBU1780 1708193 TTCATTTTTCTTTAAGTTTTGATTGATAAC-A-T 1708224 + 129 
CBU1794 1725403 TTAAGGTTTTCTTAATAAAGGCTGTTTAT--ACT 1725434 + 26 
CBU1818 1748733 TTTATTTACATTTAA--TTAAAATCATTTATTAT 1748764 + 51 
CBU1822 1753234 TTAGGATTAAATTAACATGCAGGTGTTAA--GAT 1753203 - 88 
CBU1863 1793470 TTAATATTTTTTTAATATTTGGATTTTAAG-A-T 1793439 - 69 
CBU2013 1920851 TTAATAATTTGTTAATATCGGTTTGGTAAT-A-T 1920820 - 20 
CBU2051 1957518 TTCATATATTTTTAAGCATGGCTTGGTAC--ACT 1957487 - 36 
CBUA0007 4919 TTAATTCTTCTTTAATAATATACTGATAT—CCT 4888 - 34 
 
 
 
In the second method, we used the E-block feature found in a large number of 
Dot/Icm substrates of L. pneumophila (46). One of the three consensus sequences, 
EExxE, ExE, or EEx, was found in 49 Dot/Icm substrates of Coxiella, indicating the 
usefulness of this motif as a reliable predictor of substrate candidates. Using this feature, 
we identified 328 ORFs that possess a similar motif. Of these, 122 ORFs encode 
hypothetical proteins that were retained in the candidate pool (Table 2.4). 
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Table 2.4 C. burnetii T4SS candidates possessing an E block motif. 
ID E position 
CBU0012 E_Position = [16,19,21] 
CBU0050 E_Position = [3,6,9,28] 
CBU0061 E_Position = [1,15,16,17,19] 
CBU0067 E_Position = [18,22,26,28] 
CBU0080 E_Position = [0,1,7,18,19,20] 
CBU0092 E_Position = [5,20,21] 
CBU0113 E_Position = [11,18,19,20,21] 
CBU0115 E_Position = [3,7,12,13,23] 
CBU0122 E_Position = [6,8,9,10,11,18,22] 
CBU0134 E_Position = [14,16,25] 
CBU0150 E_Position = [11,18,19] 
CBU0211 E_Position = [5,8,10] 
CBU0212 E_Position = [3,8,21,22,23] 
CBU0270 E_Position = [9,13,15,26] 
CBU0295 E_Position = [9,10,13,15,19] 
CBU0328 E_Position = [1,15,18] 
CBU0339 E_Position = [4,14,18,19] 
CBU0340 E_Position = [3,8,15,24,25] 
CBU0344 E_Position = [0,1,18,20] 
CBU0360 E_Position = [6,9,11,15,19,23] 
CBU0372 E_Position = [0,7,8,11,20,24] 
CBU0375 E_Position = [6,8,27] 
CBU0376 E_Position = [12,16,18,20,27] 
CBU0377 E_Position = [3,13,16,20,21] 
CBU0425 E_Position = [13,14,17] 
CBU0469 E_Position = [2,5,10,26] 
CBU0470 E_Position = [4,12,13,26] 
CBU0498 E_Position = [2,13,16] 
CBU0507 E_Position = [0,8,15,24,25] 
CBU0510 E_Position = [5,12,16,17,24,25] 
CBU0513 E_Position = [4,6,22,24] 
CBU0562 E_Position = [1,3,4,7] 
CBU0590 E_Position = [16,22,25] 
CBU0606 E_Position = [1,10,11,13] 
CBU0651 E_Position = [3,14,16,22,27] 
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Table 2.4 Continued  
ID E position 
 
CBU0654 
 
E_Position = [0,13,14] 
CBU0656 E_Position = [10,23,27,28] 
CBU0658 E_Position = [4,5,6,9,12] 
CBU0698 E_Position = [0,1,6,15] 
CBU0699 E_Position = [0,2,9] 
CBU0705 E_Position = [7,11,22,24] 
CBU0706 E_Position = [3,13,14,15] 
CBU0710 E_Position = [1,4,5] 
CBU0719 E_Position = [2,17,18] 
CBU0756 E_Position = [12,26,28] 
CBU0773 E_Position = [11,16,17,24] 
CBU0879 E_Position = [6,8,9,12,15,18,20] 
CBU0885 E_Position = [10,12,14,16,18,20,21] 
CBU0891 E_Position = [11,15,16,20,23] 
CBU0910 E_Position = [7,9,18,19] 
CBU0941 E_Position = [6,8,19,27] 
CBU0957 E_Position = [0,1,10] 
CBU0970 E_Position = [11,13,16] 
CBU0972 E_Position = [4,7,26] 
CBU0985 E_Position = [3,4,6,14,17,25] 
CBU1044 E_Position = [3,4,13,20,24] 
CBU1065 E_Position = [2,3,8] 
CBU1069 E_Position = [12,15,27,28] 
CBU1079 E_Position = [14,18,19,25] 
CBU1088 E_Position = [7,8,11] 
CBU1102 E_Position = [9,10,11,15,17] 
CBU1107 E_Position = [7,11,15,17,20] 
CBU1108 E_Position = [6,10,14,15,16,18,20,21] 
CBU1124 E_Position = [13,16,23,26] 
CBU1150 E_Position = [11,12,24,28] 
CBU1164 E_Position = [3,4,5,21] 
CBU1209 E_Position = [8,11,12,13,14,19] 
CBU1215 E_Position = [14,15,25,27] 
CBU1219 E_Position = [0,3,10,17] 
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Table 2.4 Continued  
ID E position 
CBU1224 E_Position = [2,5,27] 
CBU1234 E_Position = [3,8,10,25] 
CBU1295 E_Position = [0,10,11,16] 
CBU1328 E_Position = [2,3,19] 
CBU1354 E_Position = [2,4,6] 
CBU1367 E_Position = [9,12,28] 
CBU1377 E_Position = [10,11,17] 
CBU1434 E_Position = [0,17,19,28] 
CBU1463 E_Position = [2,4,6,19] 
CBU1479 E_Position = [3,5,18] 
CBU1496 E_Position = [5,6,19,21] 
CBU1525 E_Position = [4,5,13,15,22,23] 
CBU1533 E_Position = [1,5,19,22] 
CBU1546 E_Position = [6,8,20,25] 
CBU1566 E_Position = [0,7,10,26,27] 
CBU1603 E_Position = [12,24,25] 
CBU1607 E_Position = [11,15,17,20,23] 
CBU1611 E_Position = [0,12,24,25,27] 
CBU1616 E_Position = [7,10,12,22] 
CBU1620 E_Position = [4,9,11,12,14,16,18] 
CBU1659 E_Position = [7,20,21] 
CBU1660 E_Position = [3,9,10,13,16,23,28] 
CBU1662 E_Position = [5,7,16,26] 
CBU1665 E_Position = [21,22,26] 
CBU1667 E_Position = [6,7,17] 
CBU1673 E_Position = [5,8,9,22] 
CBU1677 E_Position = [6,10,12,15,19,22] 
CBU1680 E_Position = [11,20,21] 
CBU1686 E_Position = [11,15,21,22] 
CBU1705 E_Position = [3,7,14,16,25,28] 
CBU1733 E_Position = [6,8,9,28] 
CBU1754 E_Position = [2,9,15,17] 
CBU1776 E_Position = [2,4,11,12,14,15,18] 
CBU1789 E_Position = [1,3,24] 
CBU1790 E_Position = [9,12,13,14,15] 
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ID E position 
CBU1883 E_Position = [1,9,10,17,22] 
CBU1954 E_Position = [7,25,28] 
CBU1999 E_Position = [9,11,17] 
CBU2007 E_Position = [7,9,11,19] 
CBU2010 E_Position = [15,25,28] 
CBU2016 E_Position = [2,7,10,16,19,21] 
CBU2023 E_Position = [8,15,18,23,25] 
CBU2028 E_Position = [4,5,6,10] 
CBU2033 E_Position = [5,21,22] 
CBU2034 E_Position = [4,11,12] 
CBU2057 E_Position = [3,8,15,24,25] 
CBU2059 E_Position = [8,10,16,20] 
CBU2060 E_Position = [0,2,6,16] 
CBU2064 E_Position = [3,4,6,11,14,18,20] 
CBU2076 E_Position = [6,7,15,25] 
CBUA0015 E_Position = [8,12,14,16,17,18] 
CBUA0019 E_Position = [1,9,11] 
CBUA0020 E_Position = [10,19,22] 
 
 
 
Lastly, we scanned the C. burnetii genome for homologs of the recently 
identified L. pneumophila Dot/Icm substrates (117) leading to the identification of 42 
candidates, 29 (Table 2.5) of which were tested in the current study. 
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Table 2.5 L. pneumophila effectors used for the identification of homologs in C.  
burnetii 
Hit Query Hit description E 
value 
CBU0001 lpg1924 chromosomal replication initiator protein DnaA (dnaA) {Coxiella burnetii RSA 493} 0.29 
CBU0026 lpg1888 ribose 5-phosphate isomerase (rpiA) [5.3.1.6] {Coxiella burnetii RSA 493} 0.24 
CBU0027 lpg1106 acyltransferase family protein {Coxiella burnetii RSA 493} 0.17 
CBU0111 lpg1106 2-amino-3-ketobutyrate coenzyme A ligase (kbl) [2.3.1.2...     0.33 
CBU0147 lpg1684 preprotein translocase, SecA subunit (secA) {Coxiella burnetii RSA 493} 0.32 
CBU0235 lpg0021 translation elongation factor G (fusA) {Coxiella burnetii RSA 493} 0.56 
CBU0530 lpg1716 TPR domain protein {Coxiella burnetii RSA 493} 0.16 
CBU0676 lpg2539 NAD dependent epimerase/dehydratase {Coxiella burnetii RSA 493} 0.2 
CBU0682 lpg0021  conserved domain protein {Coxiella burnetii RSA 493}          0.69 
CBU0693 lpg1670 dehydrogenase, E1 component, alpha subunit [1.2.4.1] {Coxiella burnetii RSA 493} 0.52 
CBU0753 lpg0260 transporter, AcrB/AcrD/AcrF family {Coxiella burnetii RSA 493} 0.49 
CBU0845 lpg1692  UDP-glucose/GDP-mannose dehydrogenase family {Coxiella ...     0.59 
CBU0902 lpg1667 hypothetical protein {Coxiella burnetii RSA 493} 0.3 
CBU1049 lpg1959 hypothetical protein {Coxiella burnetii RSA 493} 0.12 
CBU1108 lpg0130 hypothetical protein {Coxiella burnetii RSA 493} 0.26 
CBU1160 lpg2148 TPR domain protein {Coxiella burnetii RSA 493} 0.35 
CBU1282 lpg2826  carbamoyl-phosphate synthase, small subunit (carA) [6.3...     0.15 
CBU1292 lpg1083 ankyrin repeat domain protein {Coxiella burnetii RSA 493} 0.25 
CBU1341 lpg2826 GMP synthase (guaA) [6.3.5.2] {Coxiella burnetii RSA 493}    0.5 
CBU1363 lpg1171 exodeoxyribonuclease I, putative {Coxiella burnetii RSA 493} 0.15 
CBU1370 lpg1639  hypothetical protein {Coxiella burnetii RSA 493}          0.95 
CBU1387 lpg2546 hypothetical protein {Coxiella burnetii RSA 493}             0.054 
CBU1494 lpg2555 pyridoxal phosphate biosynthetic protein PdxJ (pdxJ) {Coxiella burnetii RSA 493} 0.82 
CBU1535 lpg0375 hypothetical protein {Coxiella burnetii RSA 493} 0.88 
CBU1594 lpg2359 GatB/Yqey domain protein {Coxiella burnetii RSA 493} 4.00E-
30 
CBU1603 lpg2912 conserved hypothetical protein {Coxiella burnetii RSA 493} 0.13 
CBU1852 lpg2826 hypothetical protein {Coxiella burnetii RSA 493} 0.072 
CBU2057 lpg2546 conserved hypothetical protein {Coxiella burnetii RSA 493}     0.33 
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 T4SS-dependent translocation of candidate substrates: To determine 
Dot/Icm-dependent translocation of these candidates, each of the 234 genes was fused to 
the C-terminal end of β-lactamase on pCBTEM (20). Plasmids that direct the expression 
of the β-lactamase fusion proteins were transformed into Lp02 (10), a L. pneumophila 
strain with a functional Dot/Icm apparatus. The resulting transformants were used to 
infect U937 cells at an MOI of 30, and protein translocation was determined by β-
lactamase-mediated cleavage of the fluorescence dye CCF4-AM. Fifty-three proteins 
were found to cause more than 1% of U937 cells to display blue fluorescence. While the 
majority of these secretion substrates exhibited a low translocation rate of <10%, four 
substrates (Cbu0425, Cbu2007, Cbu1620, and CbuA0015) exhibited a high translocation 
rate of 90%. When expressed in the dotA mutant of L. pneumophila, none of these 
proteins was able to promote the delivery of the β-lacmatase into host cytosol (Fig. 2.1). 
Collectively, these results support the designation of these 53 proteins as substrates of 
the Dot/Icm T4SS substrates. 
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Figure 2.1 Dot/Icm-dependent translocation of C. burnetii T4SS substrates by L. 
pneumophila. L. pneumophila WT strain Lp02 or ΔdotA Lp03 expressing β-lactamase 
fused T4SS substrates were used to infect U937 cells at an MOI of 30. Infected cells 
were loaded with CCF4/AM and substrate translocation was determined by counting the 
number of blue cells. For substrates exhibiting translocation rates above 10%, 
approximately 1000 cells were counted; however for substrates exhibiting low 
translocation rates (less than 10%) approximately 5000 cells were counted. Results are 
presented as mean values from triplicate wells from at least two independent 
experiments. 
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To determine whether the protein substrates identified with the L. pneumophila 
surrogate host can also be recognized by the Dot/Icm transporter of C. burnetii, C. 
burnetii RSA439 or icmX::Tn was transformed with β-lactamase TEM1 fusions listed in 
Table 2.2 and the resulting transformants were used to infect THP-1 cells. Forty-eight 
hours post-infection, cells were loaded with CCF4-AM and incubated for an additional 
4h prior to imaging. RSA439 expressing β-lactamase TEM-1 each of the substrate 
fusions was positive for translocation as evident by the presence of at least 1% blue cells 
(Fig. 2.2A) for each tested substrate. Using the constitutive pCC108 and the inducible 
vector pCBTEM we were able to demonstrate translocation of eleven substrates by C. 
burnetii; however we did observe lower expression (data not shown) and lower 
translocation using the constitutive pCC108 vector, suggesting this may be due to 
weaker promoter than in comparative C. burnetii TEM vectors [8, 20]. Notably 
Cbu0069, Cbu0113, and Cbu0885 exhibited a higher translocation when expressed in the 
natural host C. burnetii. No β-lactamase translocation was observed in host cells infected 
with the RSA439 icmX::Tn (Fig. 2.2B), indicating that translocation of these C. burnetii 
T4SS substrates is dependent on a functional secretion system suggesting they are bona 
fide C. burnetii T4SS substrates. 
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Figure 2.2 Newly identified secretion substrates are secreted by C. burnetii. THP-1 cells 
were infected for 48 h with C. burnetii expressing β-lactamase fusion constructs and 
subsequently loaded with CCF4/AM as described in materials and methods. (A) 
Confocal imaging of wild-type infected cells revealed the presence of blue cells (B) 
translocation of selected substrates was absent in cells infected with the icmX::Tn, 
indicating the identified substrates are translocated into host cells in a Dot/Icm-
dependent manner. 
A. 
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Figure 2.2 Continued 
   
B.  
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 Newly identified C. burnetii Dot/Icm substrates exhibit significant plasticity 
among bacterial isolates: Different isolates of C. burnetii are associated with unique 
disease states characterized by distinct pathological features. For instance, the Dugway 
(D) rodent isolate is avirulent when compared to NMI (99), whereas the Graves (G) and 
Kearns (K) isolates establish an infection characterized by less inflammation and 
dissemination (89). Comparison of these different isolates revealed that many effector 
proteins are intact in specific group isolates but disrupted in other isolates, suggesting 
different effector proteins may be responsible for different host cell responses and 
consequently distinct disease states (9, 18, 111).  
 To compare the heterogeneity of the newly described effectors, genome 
information for NM, D, K, and G isolates was compared using PATRIC (34). Among 
the proteins identified in this study, only 12 (Cbu0270, Cbu0469, Cbu0637, Cbu0773, 
Cbu1079, Cbu1434, Cbu1566, Cbu1754, Cbu1789, Cbu2007, Cbu2016, and Cbu2076) 
are fully conserved among all isolates (Table 2.6). Further comparison between the 
isolates showed that the highest conservation exists between NMI and Dugway isolates, 
with an additional 11 substrates fully conserved.  
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Table 2.6 Genome comparisons of T4SS substrates identified in this study. Brackets 
after each ORF indicate an alternative start (AS), an N-terminal (NT) and/or C-terminal 
(CT) truncation, or frame shift (FS) compared to corresponding NMI ORF. Numbers 
following abbreviation denote length of AS, amount truncated from N- or C- terminus, 
or site of frameshift.  
 Alias in isolates  
Gene 
Locus in 
NMI 
K G Dugway Domain 
Cbu0012  
CbuK0201 (AS 
242bp) 
CbuG0281 (AS 242bp) CbuD0136 (AS 242bp) P-loop 
Cbu0069 
CbuK1982/CbuK198
3 (NT 21bp, FS 
137bp) 
 
CbuD2035 (NT 29bp, FS 
343bp) 
HRDC-like 
Cbu0080 
CbuK1976 (AS 
506bp,) 
CbuG1937 (AS 506bp, CT 
102bp) 
CbuD2028 HLH DNA-binding domain 
Cbu0113  CbuG1899  CbuD1994  PH-domain 
Cbu0183 CbuK0377 (CT 7bp) CbuG1822 (CT 86bp) CbuD1910   
Cbu0201 
CbuK0392 (NT 
77bp) 
CbuG1805 (NT 77bp) CbuD1894 (NT 77bp) Ankyrin repeat 
Cbu0212 
CbuK0401 (AS 
1019bp) 
CbuG1796 (AS 1019bp) Cbu1884 (AS 1019bp)  
Cbu0270 CbuK0462  CbuG1738  CbuD1824   
Cbu0295 
CbuK0492 (NT 
272bp, CT 305bp) 
CbuG1710 (NT 272bp) CbuD1787 (NT 17bp) SEL1 
Cbu0344 
CbuK0540 (AS 
455bp) 
CbuG1663 (NT 69bp) CbuD1734 (AS 455bp) Coiled-coil 
Cbu0372 
CbuK0563 (FS 
621bp) 
CbuG1637 (FS 700bp) CbuD1711 Fic, transmembrane domain 
Cbu0375 
CbuK0569  (NT 
209bp) 
CbuG1634 (NT 209bp) CbuD1704 (FS 468) 
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Gene 
Locus in 
NMI 
K G Dugway Domain 
Cbu0376 
 
 
CbuK0569 (AS 
27bp)   
CbuG1634 (AS 27bp) CbuD1704 (AS 515bp)  
Cbu0388  
 
 
CbuK1672/CbuK167
3/CbuK1674 (NT 
11bp, FS 975bp) 
CbuG1619 (NT 11bp, FS 
2044bp) 
CbuG1679/CbuG1680 (NT 
11bp, FS 1588bp) 
 
Cbu0393 
CbuK1668 (FS 
287bp) 
CbuG1615 (NT 142bp, FS 
559bp) 
CbuD1674 (FS 559bp) RPT1 domain 
Cbu0425 
(cirB) 
CbuK1643 (AS 
116bp, CT 539bp) 
CbuG1587 (AS 116bp) 
CbuD1648 (AS 116bp, CT 
59bp) 
 
Cbu0469 CbuK1391 CbuG1544 CbuD1609  
Cbu0513 
CbuK1341 (NT 
71bp, CT  
CbuG1498 CbuD1562  
Cbu0637 CbuK1619 CbuG1367 CbuD0648  
Cbu0665 
CbuK1593 (NT 
21bp) 
CbuG1341 (NT 21bp, CT 85bp) CbuD0675 (AS 92bp)  
Cbu0773 CbuK0643 CbuG1228 CbuD0821  
Cbu0885 CbuK0750 CbuG1117 CbuD0949 (NT 86bp) HAD-like 
Cbu1079 CbuK0945 CbuG0924 CbuD1181  
Cbu1102 
CbuK0972 (AS 
404bp, FS 1053) 
CbuG0900 (CT 111bp) CbuD1204 (AS 404bp)  
Cbu1110 
CbuK0977 (FS 
166bp) 
 
CbuD1210 (NT 53bp, FS 
166bp) 
 
Cbu1150 
CbuK1017 (AS 
57bp) 
CbuG0859 (AS 476bp) 
CbuD1247 (AS 476bp, CT 
26bp) 
Transmembrane helix hairpin 
Cbu1198  
CbuK1062 (NT 
140bp) 
CbuG0811 (NT 140bp) CbuD1287  
Cbu1434 CbuK0601 CbuG0575 CbuD0561  
Cbu1525 
CbuK1752 (AS 
152bp) 
CbuG0485 (NT 459bp, FS 
924bp) 
CbuD0461 (AS 1900bp) YebC-like 
Cbu1566 CbuK1793 CbuG0446 CbuD0422  
Table 2.6 Continued 
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Gene 
Locus in 
NMI 
K G Dugway Domain 
Cbu1576 
CbuK1806 (NT 
129bp) 
CbuG0435/CbuG0436 (FS 
902bp) 
CbuD0410  GatB/YqeY motif 
Cbu1594 CbuK1823  CbuD0395 Transmembrane helix 
Cbu1607 
CbuK1834 (NT 
242bp) 
CbuG0407 (NT 242bp, CT 
13bp) 
CbuD0383 (NT 242bp)  
Cbu1620 
CbuK1842 (FS 
240bp) 
CbuG0403 (AS 171bp) 
CbuD0378 (AS 296bp, FS 
240bp) 
 
Cbu1639 CbuK1862 CbuG0383 (FS 309bp) CbuD0358  
Cbu1665 
CbuK0343 (FS 
897bp) 
 CbuD0334  
Cbu1677 CbuK0333 CbuG0344 CbuD0324  
Cbu1685 
CbuK0326 (FS 
1060bp) 
CbuG0337 
CbuD0317  (NT 35bp, FS 
427bp)  
 
Cbu1754 CbuK0252 CbuG0136 CbuD0247  
Cbu1789 CbuK0083 CbuG0170 CbuD0015 SGL-like 
Cbu1790 
CbuK0084 (FS 
924bp) 
CbuG0171 (FS 1685bp) CbuD0016  (FS 1263bp) PRR domain 
Cbu2007 CbuK2058 CbuG2016 CbuD2108  
Cbu2013  
CbuK2064 (NT 
50bp) 
CbuG2022 (NT 50bp) CbuD2113 (NT 50bp)  
Cbu2016 CbuK2067 CbuG2025 CbuD2117  
Cbu2028 
CbuK2080 (AS 
68bp, FS 46bp) 
CbuG2038 (AS 51bp, FS 361bp) CbuD2129 (AS 51bp) WW domain-like 
Cbu2059 
(cirE) 
CbuK2105 (AS 
389bp, CT 615bp) 
CbuG2063 (NT 182bp, FS 
313bp) 
CbuD2154 (AS 389bp)  
Cbu2064 
CbuK2107 (AS 
1233bp) 
CbuG2065 (NT 22bp, CT 
112bp) 
CbuD2156 (NT 22bp)  
Cbu2076 CbuK2121 CbuG2077 Cbu2172  
CbuA001
5 
   Coiled coil 
 
CbuA001 
    
Table 2.6 Continued 
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Gene 
Locus in 
NMI 
K G Dugway Domain 
CbuA002
0 
 CbuG2038 (CT 447bp) CbuDA0049 (CT 101bp)  
 
 
It is well established that the T4SS translocation signal resides in the last 100 
residues of the C-terminus of secretion substrates. Genome comparison of these isolates 
revealed that many of these substrates have C-terminal truncations, suggesting that these 
substrates may not be translocated by specific isolates, further supporting the idea of 
different effector pools for specific C. burnetii pathotypes. Many of the substrates have 
undergone frameshifts, resulting in the creation of several pseudogenes. For example, 
Cbu0388 has undergone several frameshifts, leading to the generation of three separate 
pseudogenes in K and two pseudogenes in D. Similarly, Cbu0375 and Cbu0376 have 
undergone several mutations resulting in two separate genes in NMI, but one gene in the 
other three isolates. Such variations may correlate with the requirement of different 
effector pools at disease states during infection. 
 
 
 
 
 
Table 2.6 Continued 
 
 46 
 
Table 2.7 Phenotypes associated with C. burnetii T4SS substrates. 
 
Cbu Number Screen/Reference 
Number1 
LP 
TEM2/CB 
TEM 
Ectopic 
Localization3 
Yeast Toxicity SEAP5 Transposon 
Mutant/ 
Replication 
Defect6 
Cbu0012*  E-block 1% No Pattern No Phenotype No Phenotype Yes/ Slight 
Defecta 
Cbu0041 (cirA) 18  70% Punctate Toxic No Phenotype Yes/ No 
Intracellular 
Replication 
Cbu0069 PmrA 1% No Pattern No Phenotype No Phenotype  
Cbu0080 E-block, 12 70%/1% No Pattern No Phenotype No Phenotype  
Cbu0113  E-block 7%/50% No Pattern No Phenotype No Phenotype  
Cbu0129 18  70% Nucleus No Phenotype No Phenotype  
Cbu0175 18  20% No Pattern No Phenotype No Phenotype  
Cbu0183 PmrA 20% No Pattern No Phenotype No Phenotype  
Cbu0201*  PmrA 1% No Pattern No Phenotype No Phenotype Yes/ No Defect 
Cbu0212  E-block 10% No Pattern No Phenotype No Phenotype  
Cbu0270* E-block 1% No Pattern No Phenotype No Phenotype  
Cbu0295*  E-block, 12 2% No Pattern No Phenotype No Phenotype  
Cbu0344  E-block 5%/4% No Pattern No Phenotype No Phenotype Yes/ No Defect 
Cbu0372 E-block 20% Endoplasmic 
Reticulum 
No Phenotype No Phenotype Yes/ No Defect 
Cbu0375  E-block 35% No Pattern No Phenotype No Phenotype  
Cbu0376  E-block 7% No Pattern No Phenotype No Phenotype  
Cbu0388  PmrA 40%/1% Nucleus No Phenotype No Phenotype Yes/ No 
Intracellular 
Replicationa 
Cbu0393* PmrA 1% Nucleus No Phenotype No Phenotype  
Cbu0410 18  45% ND No Phenotype No Phenotype  
Cbu0414 18  45% No Pattern No Phenotype No Phenotype  
Cbu0425 (cirB) E-block, 12 90% Cytoplasmic No Phenotype No Phenotype Yes/ No 
Intracellular 
Replication 
Cbu0469*  E-block 1%/4% No Pattern No Phenotype No Phenotype  
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Cbu Number Screen/Reference 
Number1 
LP 
TEM2/CB 
TEM 
Ectopic 
Localization3 
Yeast Toxicity SEAP5 Transposon 
Mutant/ 
Replication 
Defect6 
       
Cbu0606  E-block 2%/2% Cytoplasmic Toxic No Phenotype  
Cbu0665 PmrA 3% Cytoplasmic No Phenotype No Phenotype  
Cbu0773   E-block 5% No Pattern No Phenotype No Phenotype  
Cbu0794 18  80% Nucleus No Phenotype No Phenotype  
Cbu0801 18  10% No Pattern No Phenotype No Phenotype  
Cbu0814 18  10% No Pattern No Phenotype No Phenotype  
Cbu0881 18  80% ND No Phenotype No Phenotype  
Cbu0885  E-block 1%/3% Cytoplasmic Toxic No Phenotype  
Cbu0937 (cirC) 18  2% Cytoplasmic No Phenotype No Phenotype Yes/ No 
Intracellular 
Replication 
Cbu1045 18  40% No Pattern No Phenotype No Phenotype  
Cbu1079   E-block 5% No Pattern No Phenotype No Phenotype  
Cbu1102  E-block 70% No Pattern No Phenotype No Phenotype  
Cbu1110 PmrA 40% No Pattern No Phenotype No Phenotype  
Cbu1150* E-block 1% No Pattern No Phenotype No Phenotype  
Cbu1198 PmrA 75% No Pattern No Phenotype No Phenotype Yes/ Slight 
Defecta 
Cbu1217 18  10% No Pattern No Phenotype No Phenotype  
Cbu1314 18  2% Nucleus No Phenotype No Phenotype  
Cbu1379* 18  1% No Pattern No Phenotype No Phenotype  
Cbu1406 18  40% Cytoplasmic No Phenotype No Phenotype  
Cbu1425* 18  1% Mitochondria No Phenotype No Phenotype  
Cbu1434* E-block 1% Cytoplasmic No Phenotype No Phenotype  
Cbu1457  18  2% ND No Phenotype No Phenotype Yes/ Slight 
Defecta 
Cbu1460 18  40% ND No Phenotype No Phenotype  
Cbu1461 18  2% Cytoplasmic No Phenotype No Phenotype  
Cbu1524 12, 18 10% Nucleus Toxic No Phenotype  
Cbu1525 E-block, 12  Cytoplasmic No Phenotype No Phenotype  
Cbu1543 18  25% Punctate No Phenotype No Phenotype  
Table 2.7 Continued 
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Cbu Number Screen/Reference 
Number1 
LP 
TEM2/CB 
TEM 
Ectopic 
Localization3 
Yeast Toxicity SEAP5 Transposon 
Mutant/ 
Replication 
Defect6 
Cbu1556 18  50% Cytoplasmic No Phenotype 0.23 ± 0.01 Yes/ No Defect 
Cbu1566   E-block 5% No Pattern No Phenotype No Phenotype  
Cbu1576 PmrA 2%/2% Endoplasmic 
Reticulum 
No Phenotype No Phenotype  
Cbu1594 Homolog 5% No Pattern No Phenotype No Phenotype  
Cbu1607  E-block 5% No Pattern No Phenotype No Phenotype  
Cbu1620  E-block 90% No Pattern No Phenotype No Phenotype  
Cbu1636 18  1% Punctate No Phenotype No Phenotype Yes/ No Defect 
Cbu1639 PmrA 4% No Pattern No Phenotype No Phenotype Yes/ No Defect 
Cbu1665*  E-block 1%/1% No Pattern No Phenotype No Phenotype Yes/ No Defect 
Cbu1677   E-block 5% No Pattern No Phenotype No Phenotype  
Cbu1685 PmrA 1%/1% No Pattern No Phenotype No Phenotype  
Cbu1751 18  50% No Pattern No Phenotype No Phenotype  
Cbu1754 E-block 2%/1% No Pattern No Phenotype No Phenotype  
Cbu1769 18  1% No Pattern No Phenotype No Phenotype  
Cbu1789*   E-block 1% No Pattern No Phenotype No Phenotype  
Cbu1790* E-block 1% Cytoplasmic No Phenotype No Phenotype  
Cbu1823 12, 18 50% No Pattern No Phenotype No Phenotype  
Cbu1825 12, 18 40% Mitochondria No Phenotype 1.70 ± 0.01  
Cbu2007  E-block 90% Cytoplasmic No Phenotype No Phenotype Yes/ No Defect 
Cbu2013  PmrA 50% Cytoplasmic No Phenotype No Phenotype Yes/ Slight 
Defecta 
Cbu2016*  E-block 1% No Pattern Toxic No Phenotype Yes/ No Defect 
Cbu2028*  E-block 1% No Pattern No Phenotype No Phenotype  
Cbu2052 (cirD) 12, 18 90% Cytoplasmic Toxic No Phenotype Yes/ No 
Intracellular 
Replication 
Cbu2059 (cirE) E-block, 12 40% Cytoplasmic No Phenotype No Phenotype Yes/ No 
Intracellular 
Replication 
Cbu2064* E-block, 12 1% No Pattern No Phenotype No Phenotype  
Cbu2076*   E-block 1% No Pattern No Phenotype No Phenotype  
Table 2.7 Continued 
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Cbu Number Screen/Reference 
Number1 
LP 
TEM2/CB 
TEM 
Ectopic 
Localization3 
Yeast Toxicity SEAP5 Transposon 
Mutant/ 
Replication 
Defect6 
       
Cbu2078 12  10% ND No Phenotype No Phenotype  
CbuA0014 12,  20   10% No Pattern No Phenotype No Phenotype  
CbuA0015  E-block, 20 90% No Pattern No Phenotype No Phenotype  
       
CbuA0020* E-block 1% Mitochondria No Phenotype No Phenotype  
 
 
C. burnetii T4SS substrates target distinct subcellular compartments in 
mammalian cells: Following translocation into a host cell, many effector proteins target 
specific subcellular compartments or decorate the CCV membrane where they interact 
with host proteins (20, 60, 61, 109, 111). To determine host subcellular compartments 
targeted by the herein identified C. burnetii T4SS substrates, C. burnetii infected or 
uninfected HeLa cells were transiently transfected with each substrate expressed as a 
fusion of EGFP. Imaging of 52 ectopically expressed substrates identified 17 substrates 
that displayed a pattern distinct from EGFP. Most of these EGFP fusions were diffusely 
localized throughout the cytosol and were excluded from the nuclei (Fig. 2A, Table 2.7). 
All of the tested substrates displayed similar localization in infected and uninfected cells 
and no protein was co-localized with the Coxiella-containing vacuole (data not shown). 
 Interestingly, we identified two substrates, Cbu0393 and Cbu0388, that traffic to 
the nucleus, indicated by colocalization with the marker Hoechst (Fig. 2.3A). 
Bioinformatic analysis of these nuclear substrates identified a potential nuclear 
Table 2.7 Continued 
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localization signal, PPTKRPRGL, in its N-terminal region beginning at the 11th residue for 
Cbu0393 (53) and KKPSKKVKIKKSKPKKKK beginning at the 922nd residue for 
Cbu0388. 
To better determine the subcellular organelles targeted by these EGFP patterned 
substrate fusions, we conducted colocalization analysis with markers of relevant 
organelles. Two substrates, Cbu0372 and Cbu1576, localized to the endoplasmic 
reticulum (ER) as evident by colocalization with the ER marker calnexin (Fig. 2.3B). 
EGFP-CbuA0020 targeted the mitochondria as evident by colocalization with the 
mitochondrial marker CoxIV (Fig. 2.3B).  
Overexpression of several substrates interferes with yeast growth: Due to its 
genetic tractability and the high level conservation of many cellular processes with 
mammalian cells, Saccharomyces cerevisiae has evolved as a useful model for studying 
bacterial effector proteins (104). A large number of bacterial effectors have been 
identified based on their ability to interfere with yeast growth (15, 18, 95) or by their 
ability to alter vesicle trafficking (23, 95). To determine whether any of the C. burnetii 
T4SS substrates are toxic to yeast, we inserted each of these genes, as well as previously 
reported substrates (20), into the galactose inducible vector pYesNTA2. S. cerevisiae 
W303, carrying C. burnetii substrates, were grown in Uracil dropout media, serially 
diluted, and spotted onto appropriate dropout agar. Using this approach we identified six 
substrates that severely impaired growth (Fig. 2.4).  
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Figure 2.3 C. burnetii secretion substrates target distinct subcellular compartments when 
ectopically expressed in HeLa cells.  Each T4SS substrate was expressed as a C-terminal 
fusion to EGFP and used for transfection of HeLa cells. (A) A diffuse cytoplasmic signal 
that excluded the nuclei or co-localization with the nucleus, here shown for Cbu2059 
and Cbu0393, respectively, could be demonstrated.  (B) Colocalization analysis 
identified two substrates (Cbu0372 and Cbu1576) that colocalize with the endoplasmic 
reticulum marker calnexin and one substrate (CbuA0020) that colocalizes with the 
mitochondrial marker CoxIV. Scale bar in merged images represents 10 µm. Arrows 
denote location chosen for inset. 
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Figure 2.4 C. burnetii T4SS substrates interfere with yeast growth. S. cerevisiae W303 
expressing C. burnetii T4SS substrates were diluted to an OD600 of 0.2 serially diluted 
and on spotted onto dropout media containing 2% glucose or 2% galactose. All strains 
exhibited similar growth under noninducing conditions, in presence of glucose, but 
exhibited significantly diminished growth on galactose containing media.  
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Overexpression of C. burnetii secretion substrates interferes with the host 
secretory pathway: One C. burnetii T4SS effector has been shown to interfere with 
vesicle trafficking by disrupting membrane trafficking using the secreted embryonic 
alkaline phosphatase (SEAP) assay (18). To determine whether other Coxiella Dot/Icm 
substrates interfere with the secretory pathway of eukaryotic cells, Hek293T cells were 
transiently transfected to express both the SEAP protein and EGFP substrate fusions. 
The ratio of extracellular to intracellular SEAP activity was calculated (Table 2.7 and 
Fig. 2.5). Three substrates, Cbu1556, Cbu1825, and CbuA0019 exhibited an 
extracellular/intracellular ratio of 0.23 ± 0.01 (P<0.0001), 1.70 ± 0.01 (P=0.0004), and 
1.36 ± 0.04 (P=0.0002) respectively, which was significantly reduced compared to the 
vector alone ratio of 4.32 ± 0.16, indicating that these C. burnetii effectors interfere with 
the host secretory pathway.   
C. burnetii T4SS substrates are essential for intracellular replication and 
CCV formation: The Legionella pneumophila Dot/Icm system is estimated to deliver 
over 250 proteins into the host cell cytosol. In the L. pneumophila model, loss of a single 
effector generally doesn’t diminish bacterial intracellular replication, suggesting a 
degree of functional redundancy (79). To determine whether individual C. burnetii T4SS 
substrates are necessary for intracellular replication and CCV maturation, we generated a 
pool of mutants using the mariner-based Himar1 transposon for random mutagenesis. 
Rescue cloning and sequencing analysis led to the isolation of 20 unique T4SS substrate 
mutants (Table 2.7 and Fig. 2.6).  
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Figure 2.5 C. burnetii secreted effectors interfere with host protein secretion. 
Hek293T cells were co-transfected with pSEAP and GFP-tagged T4SS substrates or 
vector control. Twenty-four hours post-transfection, external and internal SEAP was 
calculated.  A significant decrease in SEAP activity was noted for Cbu1556 (P<0.0001), 
CbuA0019 (P=0.0002), and Cbu1825 (P=0.0004) compared to the vector control. 
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Figure 2.6 Himar1 transposon insertion into C. burnetii T4SS substrate genes. To 
generate a large pool of C. burnetii Tn mutants, NMII was transformed with pKM225, 
and the resulting transformants were expanded and rescue cloned and three E. coli 
colonies were sequenced per transformation. The schematic shows the insertion of the  
Himar1 transposon (blue) into the T4SS substrate genes (purple) 
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Figure 2.6 Continued 
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Figure 2.6 Continued 
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Figure 2.6 Continued 
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Figure 2.6 Continued 
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Figure 2.6 Continued 
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To determine the effects of each of these mutations on bacterial intracellular 
replication or CCV formation, we infected J774A.1 and HeLa cells with these mutants 
and monitored bacterial growth. Whereas several of the substrates were dispensable for 
intracellular replication, six substrate mutants (Cbu0041, Cbu0388, Cbu0425, Cbu0937, 
Cbu2052, and Cbu2059) were unable to replicate in J774A.1 (Fig. 2.7A) or HeLa cells 
(data not shown). These mutants displayed a growth phenotype similar to that of the 
RSA439 icmX::Tn strain. An additional four substrate mutants (Cbu0012, Cbu1198, 
Cbu1457, and Cbu2013) were capable of replication in J774A.1; however, the bacterial 
yield was significantly reduced compared to the parental RSA439 (Fig. 2.7B). None of 
these mutants were capable of forming the characteristic large CCV and instead resided 
in a tight fitting vacuole that did not expand even at late timepoints following infection 
(Fig. 2.7C). None of these mutants displayed a growth defect when cultured axenically 
in ACCM-2 (Fig. 2.8A), indicating that the growth defect is not caused by impairment in 
general bacterial physiology, but likely the inability of the mutants to properly interact 
with host cellular processes necessary for the establishment of replicative niche.  
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Figure 2.7 Individual C. burnetii effector proteins are essential for intracellular 
replication and CCV formation. NMII C. burnetii was transformed with the Himar1 
transposon and the resulting clonal substrate mutants were used to infect J774A.1 Tn 
insertion into Cbu0041 (cirA), Cbu0388, Cbu0425 (cirB) Cbu0937 (cirC), Cbu2052 
(cirD), and Cbu2059 (cirE) resulted in an inability to replicate intracellularly; however 
(B) Tn insertion into Cbu0012, Cbu1198, Cbu1457, and Cbu2013 resulted in reduced 
intracellular replication compared to RSA439. To determine if co-infection with parental 
NMII would rescue the Tn mutants’ growth defect, HeLa cells were infected with an 
MOI of 100 of each strain and incubated for seven days. Images were captured using a 
Nikon A1 confocal microscope and at least 100 infected cells were imaged per 
experiment. Co-infection with wild-type resulted in significant replication for both wild-
type and Tn substrate mutant whereas cells only infected with the substrate mutant did 
not exhibit significant replication. Scale bars represent 6µM.    
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Ten substrate mutants exhibited an inability to productively infect host cells. It 
was recently demonstrated that co-infection of an icmD::Tn with the isogenic NMII 
rescues this growth defect by supplying the T4SS functions in trans (6). If the inability 
of these effector mutants to replicate intracellularly is due to the loss of an individual 
effector function, supplying the effector function in trans should similarly rescue their 
growth defect. Confocal images of cells infected with individual substrate mutants 
resulted in the formation of tight fitting vacuoles that do undergo expansion at late time 
points of infection (Fig. 2.7C). However, co-infection of Cbu0041, Cbu0388, Cbu0937, 
Cbu2052, Cbu2059, Cbu0425, and Cbu1457 effector mutants with the isogenic NMII 
resulted in the formation of CCVs that consisted of roughly equivalent numbers of 
substrate mutant (red) and NMII (blue) (Fig. 2.7C), indicating that these Tn effector 
mutants are capable of replicating in a vacuole co-inhabited by the parental strain. No 
co-infected cells were observed for Cbu0012, Cbu1198, and Cbu2013. Therefore, at this 
time, we were unable to confirm that these individual substrates are necessary for 
intracellular replication and CCV formation.  
To further verify that the affected substrate genes in these mutants are 
responsible for the observed phenotypes, we tested three additional Himar1 insertions 
each for Cbu0041, Cbu0425, Cbu0937, Cbu2052, and Cbu2059 that were inserted in the 
same position (Fig. 2.8B), but were obtained from separate individual transformations. 
Growth curve analysis of each mutant in J774A.1 resulted in no intracellular replication 
(Fig. 2.8), suggesting that the observed growth defect is due to the loss of that individual 
effector protein and is unlikely the result of a random point mutation at a secondary site 
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or due to polar effects. Given their crucial role in intracellular replication and CCV 
formation, we renamed Cbu0041, Cbu0425, Cbu0937, Cbu2052, Cbu2059, as cirA-E 
(Coxiella effector for intracellular replication), respectively. Overall these results 
indicate that the growth defect observed for cirA-E is due to the loss of an individual 
effector protein and thus results in the inability of the mutant bacteria to form the proper 
CCV. 
Discussion 
 Using multiple bioinformatics predictions and analyses, we obtained 234 
candidates for substrates of the Coxiella Dot/Icm T4SS. Translocation assays with L. 
pneumophila as surrogate host resulted in the identification of 53 substrates that were 
secreted in a Dot/Icm-dependent manner, representing a 22.6% success rate for substrate 
identification. Seven substrates identified using this screen (Cbu0080, Cbu0295, 
Cbu0425, Cbu1525, Cbu2059, Cbu2064, and CbuA0015) were previously identified as 
Dot/Icm secretion substrates in two independent studies based on  genomic (18) and 
plasmid QpH1 (109) screens. The identification of 46 novel substrates highlights the 
effectiveness of using computational approaches. However, the use of a PmrA consensus 
sequence and E-block motifs did not rediscover many of the previously reported 
substrates (18, 20, 83, 109, 111). This suggests that the features governing the 
recognition of substrate secretion by the Dot/Icm complex is highly diverse and that their 
expression regulation differs significantly. 
Cbu0201 (ankC) was previously reported as negative for secretion (83, 111); 
however, we observed a 1% translocation rate for this substrate using L. pneumophila as 
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Figure 2.8 C. burnetii growth defects are due to the loss of individual effector proteins. 
(A) C. burnetii T4SS substrate mutants were used to inoculate ACCM-2 using 1.0 X 106 
bacteria/ml. Loss of individual effectors had no effect on axenic culture. (B) To verify 
that the growth defect is due to loss of individual effector proteins, three additional 
mutants obtained from separate transformations were used to infect J774A.1 cells at an 
MOI of 100. Genome equivalents were calculated at d1, d4, and d7. Each isolated Tn 
mutant exhibited a similar phenotype, indicating the inability to replicate intracellularly 
is due to the loss of a specific individual effector and is not likely attributable to another 
mutation at a secondary site. 
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Figure 2.8 Continued 
B. 
0 3 5 7
1.0×10 07
1.0×10 08
1.0×10 09
1.0×10 10
1.0×10 11
1.0×10 12
RSA439
icmX::Tn
Cbu0388::Tn
Cbu1198::Tn
Cbu0041 (cirA)::Tn
Days Post-Inoculation
G
e
n
o
m
e
 E
q
u
iv
a
le
n
ts
/m
l
 
 
cirA
d0 d3 d7
1.0×10 03
1.0×10 04
1.0×10 05
1.0×10 06
1.0×10 07
1.0×10 08
1.0×10 09
RSA439
cirA::Tn-2
cirA::Tn-3
cirA::Tn-4
Days Post-Infection
G
e
n
o
m
e
 E
q
u
iv
a
le
n
ts
/W
e
ll
 
 
 
 
 
 67 
 
Figure 2.8 Continued 
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Figure 2.8 Continued 
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a surrogate host. The discrepancies between these studies can most likely be attributed to 
a difference in secretion assays used. Here we used the β-lactamase TEM-1 assay and 
observed a 1% translocation, whereas the previous studies used a CyaA assay (83, 111). 
The different results obtained between these studies highlight the importance of using 
multiple translocation approaches to more comprehensively define protein substrates of 
the Dot/Icm system. Although our results suggest ankC is T4SS substrate of Coxiella, 
further verification using independent secretion assays in C. burnetii is needed. 
Following translocation into the host cell, many proteins traffic to specific 
subcellular compartments where they modulate the activity of specific host proteins. 
Subcellular localization has been used in numerous studies as an important starting point 
for elucidating effector function (15, 18, 23, 109). We transiently transfected infected 
and uninfected HeLa cells with EGFP-tagged T4SS substrates. Of the 52 substrates 
examined, 16 fusions displayed a pattern distinct from EGFP. Whereas the vast majority 
of these patterns were evenly distributed throughout the cytosol, distinct localization of 
several substrates was observed.  
The long-standing coexistence between bacterial pathogens and eukaryotic host 
has facilitated the evolution of novel methods for subverting the host innate immune 
response (40). In the past decade, several bacterial effectors have been identified that 
traffic to the nucleus where they provoke histone modifications and facilitate chromatin 
remodeling (32, 39, 85, 116), suggesting that targeting host gene expression is a 
conserved mechanism used by intracellular pathogens to combat the host defense. Given 
that many intracellular pathogens secrete nuclear effector proteins, we assessed 
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colocalization of our T4SS substrates with the nuclear marker Hoechst. We identified 
two substrates, Cbu0393 and Cbu0388, which trafficked to the nucleus and encoded a 
predicted nuclear localization signal. Interestingly several additional studies recently 
identified three other C. burnetii nuclear substrates; Cbu1524 (caeA), Cbu1314, and 
CbuK1976, suggesting C. burnetii encodes a large repertoire of nuclear effectors (18, 20, 
52).  
C. burnetii has been shown to overcome host defense and to inhibit host cell 
death by actively promoting host cell viability by inducing pro-survival pathways. 
Modulation of the interplay between Beclin 1 and Bcl-2 (107) and sustained activation 
of Akt and Erk1/2 (110), have been proposed to be mediated by T4SS effectors. This 
hypothesis is supported by the characterization of AnkG, a C. burnetii T4SS effector that 
was found to inhibit apoptosis by modulating p32 (60). An additional 2 effector proteins, 
nuclear localized caeA (Cbu1524) and mitochondrial localized caeB (Cbu1532), were 
similarly found to prevent host cell apoptosis (52). In the current study we identified 
another substrate, CbuA0020 that colocalized with the mitochondrial marker CoxIV. It 
will be interesting to determine whether this mitochondrial-localized protein is similarly 
capable of inhibiting host cell apoptosis. 
Ectopic expression in yeast has been routinely used to study bacterial effector 
proteins. For example, 79 Legionella effectors are able to significantly impair yeast 
growth (43), a phenotype that has been exploited to analyze their biochemical function 
(35, 100, 108). The identification of Coxiella T4SS substrates capable of inhibiting yeast 
growth will provide additional tools in determining their role in infection. Similarly, 
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specific targeting of these proteins to distinct host organelles will facilitate future 
functional analysis.  
Recent advances in the field, including the ability to culture the bacteria 
axenically in ACCM-2 (80), to genetically manipulate the pathogen using a Himar1 
transposon (7), and recently the adaptation of a loop-in-loop-out mediated site-directed 
mutagenesis (8) have significantly advanced our understanding of C. burnetii 
pathogenesis. By applying these tools to our study we were able to successfully generate 
and isolate a pool of transposon mutants which included 20 T4SS substrate mutants. 
Growth curve analysis of each mutant revealed that ten of these substrates mutants were 
unable to replicate intracellularly or form a characteristic CCV. This intriguing finding 
suggests less functional redundancy than observed for the comparable L. pneumophila 
model in which only a few effectors, including SdhA (56) and AnkB (2), have been 
shown to be essential for intracellular replication in mammalian cells. Furthermore, a 
recent study by O’ Connor et al. (79) demonstrated that deletions of large segments of 
the L. pneumophila genome results in no impairment in mammalian intracellular 
replication, however these mutants were significantly impaired in replication in 3 
amoeba species. The differences in effector redundancy between these two related 
bacterial species can mostly be attributed to the fact that L. pneumophila is an accidental 
human pathogen that has developed a large effector repertoire for growth in a diverse 
array of protozoa species, whereas C. burnetii is a highly adapted mammalian pathogen 
that is capable of replicating in numerous vertebrate species (79).  
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 Each of the cirA-E::Tn mutants were observed to be incapable of efficient 
intracellular replication, unless in cells coinfected with the isogenic NMII. Recent 
studies have shown that coinfection of L. pneumophila ankB mutant with wild-type L. 
pneumophila was able to rescue the growth defect associated with this mutant by 
supplying the effector in trans, highlighting the importance of individual effector 
proteins in generating the appropriate intracellular niche. Similarly, it was demonstrated 
that the growth defect associated with a C. burnetii icmD::Tn mutant could also be 
rescued by coinfection with the wild-type (6). The ability of NMII to rescue the specific 
Tn mutants supports the hypothesis that the growth defect observed is the result of the 
mutants inability to form the appropriate CCV that results from the loss of an individual 
effector protein. This is an intriguing finding and highlights the importance of individual 
effector proteins in modulating interactions with the host to facilitate the appropriate 
intracellular niche.  
Genome comparison for cirA-E revealed that only four substrates (cirA, cirB, 
cirC,  and cirD,) are fully conserved among the different C. burneti pathotypes (20), 
whereas significant heterogeneity exist among cirE. However, cirE has undergone 
several frameshifts, raising the question is this substrate secreted by other C. burnetii 
pathotypes? It will be interesting to determine if each of these substrates are translocated 
by each of the pathotypes and if the RSA439 mutants can be complemented by the 
corresponding K, G, or D DNA. 
 In conclusion we show that C. burnetii encodes a large, unique repertoire of 
T4SS substrates that traffic to distinct subcellular compartments and potentially interfere 
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with crucial host cell processes. Through the use of a Himar1 transposon, we isolated 20 
individual T4SS substrate mutants, ten of which were found to be essential for efficient 
intracellular replication and CCV formation, indicating a lack of effector functional 
redundancy. Further study of these effectors, including mutant complementation, 
generation of site-directed mutants, and identification of host binding partners, is 
currently underway to better address how each effector facilitate bacterial pathogenesis 
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CHAPTER III 
TARGETING OF RHO GTPASES BY CIRA, A T4SS SUBSTRATE OF COXIELLA 
BURNETII ESSENTIAL FOR INTRACELLULAR REPLICATION 
Summary 
Coxiella burnetii, the etiological agent of acute and chronic Q fever in humans, is 
an intracellular pathogen that replicates in an acidified parasitophorous vacuole derived 
from host lysosomes. Central to pathogenesis is a specialized Dot/Icm secretion system 
that delivers bacterial virulence proteins, termed effector proteins, into the host cell 
cytosol.  Recently we reported the identification of 85 T4SS substrates, 6 of which were 
toxic to yeast. Of these toxic substrates, Cbu0041 (CirA), was determined to be 
necessary for intracellular replication and CCV formation. To identify the pathway 
targeted by CirA, S. cerevisiae overexpressing CirA was co-transformed with pYEp13 
yeast genomic library. Using this approach we identified Rho GTPases as suppressors of 
CirA toxicity. In mammalian cell, ectopically expressed CirA localized to the plasma 
membrane, induced cell rounding, and disrupted the actin cytoskeleton. Phage display 
analysis identified Rho GTPase activating protein 29 as a potential binding partner of 
CirA. The finding that a Coxiella effector protein targets specific Rho GTPases is 
consistent with a recent study that demonstrated F-actin and the active forms of both 
RhoA and Cdc42 are recruited to the CCV and is essential for formation of the 
characteristically spacious CCV.  
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Introduction 
Coxiella burnetii is a naturally obligate intracellular pathogen that is the 
causative agent of Q fever in humans. The primary route of infection is through 
inhalation of contaminated aerosols, which typical results in acute Q fever, a debilitating 
flu-like illness that is generally self-limiting and readily resolves without antibiotic 
treatment. However, in rare circumstances persistent infection can lead to chronic Q 
fever that presents as endocarditis or hepatitis (106). While the number of reported cases 
of acute Q fever in the United States is relatively low, a marked increase occurred in 
1999 when Q fever became a reportable disease and a recent outbreak of Q fever in the 
Netherlands resulted in over 4,000 confirmed cases with 20% of patients requiring 
hospitalization (105). The dramatic increase in reported cases suggests C. burnetii is an 
emerging pathogen and highlights our lack of understanding of C. burnetii virulence 
factors. 
Inhalation of C. burnetii by a mammalian host results in actin-dependent 
endocytosis and internalization in an early endosome. While numerous intracellular 
pathogens actively subvert the default endocytic pathway to establish a unique host-
derived vacuole, C. burnetii generally follows the default trafficking pathway to 
establish a Coxiella-containing vacuole (CCV) derived from the host lysosomal network. 
Generation of this unique replicative compartment requires active bacterial protein 
synthesis for homotypic and heterotypic fusions associated with generation of spacious 
CCV that occupies the majority of the host cytoplasmic space (17, 45, 88). 
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Central to pathogenesis is a specialized type IVB secretion system (T4SS) that is 
homologous to the Dot/Icm secretion system of L. pneumophila. In Legionella this 
system is composed of 26 dot/icm (defect in organelle trafficking/intracellular 
multiplication) genes that together form a pilus-like structure that spans the bacterial 
inner and outer membrane to deliver bacterial virulence proteins into the host cell 
cytoplasm. Coxiella encodes 23 of these Dot/Icm components. Recent advances 
including axenic culture (80) and genetic manipulation (7, 8) have confirmed that, like 
the Legionella system, the Dot/Icm system of C. burnetii is essential for intracellular 
replication, CCV formation, effector translocation, and modulation of host apoptosis (6, 
18). 
To date over a hundred T4SS substrates have been identified in C. burnetii using 
bacterial-two-hybrid (20), bioinformatics (20, 57, 83, 113), plasmid localization (67, 
109) and genomic assays (18). Large-scale screening of these substrates has 
demonstrated that these substrates traffic to distinct subcellular compartments, interfere 
with crucial host processes, and importantly are less functionally redundant when 
compared to the Legionella model (18, 20, 57, 67, 109, 113). While phenotypes 
identified using these large scale screens can aid in effector characterization, the function 
of many of these substrates remains unknown. Three effector proteins CaeA, CaeB, and 
AnkG, were recently reported to play a role in modulating host survival by interfering 
with apoptosis (52, 60) whereas a fourth effector, CvpA, was recently shown to engage 
the clathrin mediated transport pathway (57). 
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The Rho family of small GTPases is found in all eukaryotic organisms and plays 
an integral role in actin organization, cell adhesion, vesicle trafficking, and migration 
(86). These molecules act as molecular switches that cycle between an active GTP-
bound form and an inactive GDP-bound form (86, 101).  Cycling between these forms is 
tightly regulated by 3 families of proteins: 1) guanine nucleotide exchange factors 
(GEFs) active Rho GTPases by displacing Mg2+ to promote GDP release and GTP 
binding, 2) GTPase activating proteins (GAPs) inactivate Rho GTPase by inserting a 
water molecule into the catalytic pocket to stimulate intrinsic GTPase activity, and 3) 
guanine nucleotide-dissociation inhibitors (GDIs) control subcellular localization to 
inhibit interaction with downstream targets (86, 96, 101).  
In the current study we demonstrate that the toxicity of CirA is suppressed by 
overexpression of small Rho GTPases including Rho1, Rho2, Rho4, and Cdc42. 
Furthermore, overexpression of CirA in mammalian cells resulted in cell rounding, 
cytoskeleton disruption, and ultimately apoptotic cell death. Phage display analysis 
revealed that CirA targets Rho GAP 29, suggesting that CirA acts upstream of the Rho 
GTPase. 
Materials and methods 
Bacteria and host cell lines: Bacteria and yeast used for this study are listed in 
Table 3.1. C. burnetii Nine Mile phase II (NMII), clone 4 (RSA439) was propagated in 
ACCM-2 under microaerophilic conditions as previously described (80). When required, 
350 µg/ml kanamycin or 5 µg/ml chloramphenicol was added.  
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Table 3.1 Bacterial and yeast strains used in this study. 
Strains Phenotype or Description References 
C. burnetii   
RSA439  Phase II, Clone 4 (NMII) (90) 
RSA439 MK2 CBU0041::Tn, Cmr (113) 
RSA439 MK21 icmX::Tn, Cmr (113) 
RSA439 MK22 Intergenic Cbu0179-Cbu0180::Tn, Cmr This study 
E. coli   
DH5α F´(Φ80d(lacZ)M15), recA1, endA1, gyrA96, thi1, hsdR17 (rk-mk+), 
supE44, relA1, deoR, (lacZYA-argF), U169 
Stratagene 
S. cerevisiae   
W303 MATa ura3-I leu2-3,112 his3-11,15 trpl-1 ade2-1 cad-100 rad5-535 (29) 
 
 
 
 
HeLa, Hek293T, and J774A.1 cells were cultured in DMEM with 10% FBS. All 
cell lines were maintained at 37°C with 5% CO2.  
Complementation of CirA::Tn: The 1169P-KanR cassette was PCR amplified 
from pMiniTn7-Kan (8) and cloned into pKM244 (113) to generate pKM244-KanR. The 
ORF Cbu0041 (cirA) was PCR amplified and cloned into the SalI/KpnI of pCMV-
DYKDDDDK-C (Clontech) to generate a C-terminal fusion to Flag-tag. The resulting 
fusion protein was amplified and cloned into the SalI/SphI site of pKM244-KanR to 
generate pMW-cirA. 
Axenically cultured RSA439 MK2 (Cbu0041::Tn) (113) was washed twice and 
re-suspended in distilled water to approximately 1010/ml. Electrocompetent bacteria 
were mixed with 10 μg pMW-Cbu0041 and electroporated as previously described (80). 
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After 7 d, individual colonies were expanded in ACCM-2 and screened by Western 
blotting for expression of the Flag-tagged fusion. 
To determine if plasmid complementation of RSA439 MK2 rescued the observed 
growth defect, HeLa cells where seeded into 24-well glass bottom plates at 105/ml. After 
24 hr, cells were infected in triplicate with an MOI of 50 with C. burnetii (RSA439), 
RSA439 Ig0179::Tn, RSA439 icmX::Tn, RSA439 cirA::Tn, or RSA439 cirA::Tn pMW-
cirA. At 7 d post-infection, cells were fixed with 4% formaldehyde for 10min and nuclei 
were visualized with 1X Hoechst. 
Immunofluorescence: To assess localization of CirA, HeLa cells where seeded 
in triplicate into 24-well glass bottom plates at 105/ml. Cells were transfected with 
Lipofectamine following the manufactures instructions. Twenty-four hr post-
transfection, cells were fixed with 4% formaldehyde for 10 min, permeabilized with 
0.1% triton-X 100 for 5 min, and nuclei were visualized with 1X Hoechst. To assess co-
localization with RhoA and Cdc42, cells were co-transfected and stained with anti-myc 
antibodies (Thermo) and Alexa Fluor® 555 secondary antibodies (Cell Signaling). Actin 
was visualized using Alexa Fluor® 555 or Alexa Fluor® 647 conjugated Phalloidin 
(Life Technologies). Fluorescence images were acquired with a Nikon-A1 microscope 
using the 60X oil immersion object and images were processed using NIS-Elements 
Software. Results were tabulated from triplicate wells with at least 50 transfected cells 
per experiment. Similar results were obtained from at least 3 independent experiments. 
Yeast suppressor screen to identify host proteins capable of suppressing 
CirA toxicity: CirA was introduced into pYesNTA2 as BamHI/SalI fragments and 
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toxicity was assessed by serially diluting and spotting on uracil dropout media 
containing galactose as the carbon source (113, Table 3.2). The pYEp13 genomic library 
(ATCC no. 37323) was introduced into S. cerevisiae W303 (pGal::cirA) and the 
resulting transformants were plated on uracil leucine dropout media containing galactose 
as previously described (100). From a transformation yielding 2.0 X 106 transformants, 
53 potential suppressors were isolated. To verify suppression, plasmids were isolated, 
and retransformed into S. cerevisiae W303 (pGal::cirA). Of these, 11 (pSup1-pSup11) 
consistently suppressed the toxicity of CirA. Suppressor plasmids were sequenced using 
pYEp13 seq F (ACTACGCGATCATGGCGA) and pYEp13 seq R 
(TGATGCCGGCCACGATGC) and results were analyzed using the yeast genome 
database (http://yeastgenome.org).  
Individual ORFs from the plasmids that consistently suppressed toxicity (pSup1-
pSup7) or members of the Rho GTPase family (Rho1-5, Cdc42) were introduced into 
p415ADH (73) as BamHI/SalI or PstI/SmaI fragments. Individual plasmids were 
transformed into W303 (pGal::cirA) and the resulting transformants were serially diluted 
and spotted on uracil leucine dropout media.  
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Table 3.2 Plasmids used in the study. 
Plasmid Description References or Source 
pKM225 pMW1650, com1p-TnA7, groESp-mCherry, com1p-cat, CmR Mertens et al. (Manuscript In 
Prep) 
pKM244 pJB908a, groESp-mCherry, com1p-cat, CmR, AmpR Mertens et al. (Manuscript In 
Prep) 
pKM244Kan 
pMW-CirA 
 
Ectopic expression plasmids 
pJB908a, groESp-mCherry, com1p-cat, CmR, AmpR, p1169-KanR 
pKM244Kan-CirA 
This study 
This study 
 
 
pEGFP-C1 C-terminal fusion to EGFP, kanr Clontech 
pEGFP-CirA pEGFP-C1::Cbu0041 (20) 
pRK5-myc-RhoA WT pRK5-myc::RhoA, carbr Addgene 12962 
pRK5-myc-RhoA CA pRK5-myc::RhoA Q63L, carbr Addgene 12964 
pRK5-myc-RhoA DN pRK5-myc::RhoA T19N, carbr Addgene 12963 
pRK5-myc-Cdc42 WT pRK5-myc::Cdc42, carbr Addgene 12972 
 
Yeast toxicity plasmids   
p415ADH pGal, carbR, Leu2 (73) 
P415ADH-Rho1 P415ADH::rho1 This study 
P415ADH-MRP2 P415ADH::mrp2 This study 
P415ADH-Met16 P415ADH::met16 This study 
P415ADH-Nut2 P415ADH::nut2 This study 
P415ADH-Jip5 P415ADH::jip5 This study 
P415ADH-Rho2 P415ADH::rho2 This study 
P415ADH-Rho3 P415ADH::rho3 This study 
P415ADH-Rho4 P415ADH::rho4 This study 
P415ADH-Rho5 P415ADH::rho5 This study 
P415ADH-Cdc42 P415ADH::cdc42 This study 
pYESNTA pGal, CarbR, Ura (113) 
pYESNTA-CirA pYESNTA::CirA (113) 
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Phage display: To identify the mammalian target of CirA, we employed a 
modified pull-down phage display. Hek293 cells were transfected using Lipofectamine 
with EGFP-CirA or EGFP alone per the guidelines outlined by the manufacture. 
Twenty-four hr post-transfection, cells were lysed with lysis buffer (50 mM Tris HCl, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% TRITON X-100) and incubated at 4°C 
overnight with protein G magnetic beads (Invitrogen). Immunoprecipitation (IP) 
reactions were washed and blocked with 3% BSA. A 8mer cyclic phage library was 
incubated with EGFP alone and following 1 hr incubation, the pre-cleared library was 
incubated with the CirA IP. Two hr post-inoculation the beads were washed with 0.01% 
Tween in PBS, eluted using 10 mM glycine pH3.1, and the eluent was used to infect an 
E. coli K91 culture.  Twenty-four hr post-inoculation, the phage was purified from the E. 
coli K91 culture using NaCl/PEG precipitation. The purified phage was used to re-pan 
IPs for a total of 3 rounds. During RII and RIII, 50 plaques were picked, PCR amplified, 
and sequenced. Results were tabulated by calculating enrichment between RII and RIII. 
Phagocytosis assay: To rule out differences in uptake between the strains, 
bacteria were stained with CFSE following the manufactures guidelines (Life 
Technologies). Bacteria were enumerated as previously described (113) and an MOI of 1 
was used to infect J774A.1 macrophages seeded at 105/ml in glass bottom 24-well 
dishes. Four hr post-infection, cells were washed 3 times with PBS and extracellular 
fluorescence was quenched using trypan blue. Cells were counted using a Nikon-A1 
microscope using the 60X oil immersion objective lens.  At least 200 cells were counted 
per well with at least 3 wells per experiment. Similar results were obtained from at least 
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3 independent experiments. Percent infection was tabulated by counting the number of 
infected cells compared with the total number of cells. 
Results 
 
CirA is necessary for intracellular replication and CCV formation: We 
previously reported the identification of over 80 T4SS substrates, 10 of which exhibited 
a growth defect in cell culture (113). Co-infection with wild-type bacteria rescued the 
growth defect for 5 of these Tn mutants, suggesting the observed growth defect is due to 
the loss of an individual effector protein. Plasmid complementation of cirA::Tn mutant 
rescued intracellular replication and CCV formation (Fig. 3.1). These results indicate 
that CirA is a T4SS effector that is essential for intracellular replication and CCV 
formation.  
Overexpression of the small GTPases Rho1 and Cdc42 suppress the toxicity 
CirA: To identify the host proteins targeted by CirA, we conducted a yeast suppressor 
screen to identify proteins that, when overexpressed, were capable of suppressing CirA 
toxicity. S. cerevisiae, expressing CirA from a galactose inducible promoter, was 
transformed with the pYEp13 yeast genomic library. From a transformation yielding 2.0 
X 106 transformants, 53 colonies were isolated, 11 of which consistently suppressed the 
toxicity of CirA (Fig. 3.2A). Sequencing of each pSup revealed that over half of these 
clones contained identical plasmids (pSup1-pSup7), each encoding 5 full yeast orfs and a 
truncated mms1 (Fig. 3.2B). Individual expression of each full-length orf found in 
pSup1-7 revealed that only the small GTPase Rho1 was capable of suppressing CirA, 
suggesting Rho1 is the cellular target of CirA (Fig. 3.2C). 
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Figure 3.1 Plasmid complementation of cirA::Tn rescues both intracellular replication 
and CCV formation. (A) Confocal images of HeLa cells infected at an MOI of 50 with 
an intergenic Tn mutant (Ig0179-0180), cirA::Tn, and complemented cirA::Tn pMW-
CirA for 7 d. Images were captured with a Nikon A1 confocal microscope, with a least 
100 infected cells observed per experiment. 
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Figure 3.2 Overexpression of the small GTPases suppress the toxicity of CirA. (A) S. 
cerevisiae W303, overexpressing CirA from a galactose-inducible promoter, was 
transformed with the yeast genomic library pYEp13.  Eleven clones (pSup1-pSup11) 
were isolated that consistently suppressed the toxicity of CirA. (B) Sequencing of the 
suppressor plasmids revealed that 7 of these plasmids (pSup1-pSup7) were identical and 
predicted to contain 5 full-length yeast orfs and a truncated mms1. (C) Each orf from 
pSup1 were PCR amplified and cloned into p415-ADH and the resulting constructs were 
transformed into CirA expressing yeast. Only expression of Rho1 was capable of 
suppressing CirA toxicity. (D) To determine if suppression is specific to Rho1, each Rho 
GTPase from S. cerevisiae was independently expressed in CirA harboring yeast. Only 
the GTPases Rho1, 2, 4, and Cdc42 were able to suppress CirA toxicity. 
 
A. 
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Figure 3.2 Continued 
B.  
 
C. 
 
D. 
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While the majority of the isolated suppressor plasmids contained Rho1, 1 
plasmid (pSup8), contained the Rho GTPase Cdc42. The finding that another suppressor 
plasmid contained alternate Rho GTPase capable of suppressing CirA toxicity suggested 
CirA might target multiple members of the Rho GTPase family. S. cerevisiae encodes 6 
Rho GTPases (Rho1-5 and Cdc42) of which only Rho1 and Cdc42 are essential. To 
determine if CirA targets multiple Rho GTPases, we independently expressed each Rho 
GTPase in the CirA expressing yeast. Expression of only Rho1, Rho2, Rho4, or Cdc42 
was able to suppress the toxicity of this effector protein (Fig. 3.2D). 
CirA co-localizes with F-actin and the small GTPases RhoA and Cdc42: 
Suppression of CirA toxicity by members of the Rho family of GTPases suggest that 
these are the cellular targets of CirA. Mammals encode 22 Rho GTPases, of which 
RhoA, Cdc42, and Rac1 are the most widely studied (86). To identify subcellular 
localization in mammalian cells, CirA was expressed as a C-terminal fusion to EGFP 
and the resulting construct was used to transiently transfect HeLa cells. EGFP-CirA 
predominately localized to the plasma membrane (Fig. 3.3A). To better assess the 
localization of CirA, cells were co-transfected with either myc-RhoA (mammalian 
homologue to Rho1) or myc-Cdc42 and F-actin was visualized by phalloidin staining. 
CirA co-localized with both F-actin (Fig. 3.3B) and the Rho GTPases RhoA (Fig. 3.3C) 
and Cdc42 (Fig. 3.3D). No co-localization was noted between EGFP alone and F-actin 
or Rho GTPases RhoA and Cdc42 (Fig. 3.3B-D). 
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Figure 3.3 Ectopically expressed EGFP-CirA localizes to the plasma membrane and co-
localizes with F-actin and Rho GTPase RhoA and Cdc42. (A) CirA was expressed as a 
C-terminal fusion to EGFP and used to transiently transfect HeLa cells. (B) 
Representative micrographs of HeLa cells transfected with EGFP-CirA (green) and 
immunostained with Alexa Fluor 555 Phalloidin or co-transfected with myc-tagged 
RhoA or Cdc42 (red). White boxes denote the area used for insets.  
 
A. 
 
B. 
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Figure 3.3 Continued 
C. 
 
D. 
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Overexpression of CirA leads to cell rounding and disruption of the actin 
cytoskeleton: To better explore the impact of CirA on the mammalian host cytoskeleton, 
cells were transfected and scored for phenotypes associated with perturbation of the 
actin cytoskeleton. Overexpression of CirA in HeLa cells (Fig. 3.4A) and Hek293 cells 
(data not shown) resulted in cell rounding and detachment from the culture dish. By 24 
hr post-transfection, 86% of CirA expressing cells were rounded and detached, whereas 
only 8% of cells transfected with the negative control, EGFP alone, were rounded by this 
timepoint. Phalloidin staining revealed that cells transfected with CirA possessed 
reduced stress fibers whereas cells transfected with EGFP alone exhibited robust stress 
fibers (Fig. 3.3B and 3.4B). Only 24% of CirA transfected cells possessed stress fibers 
whereas 85% of cells transfected with the negative control exhibited normal stress fiber 
formation. Collectively these results suggest that overexpression of CirA perturbs the 
actin cytoskeleton of the host cell. 
Phage display identified RhoGAP 29 as the mammalian target of CirA: The 
use of a yeast suppressor screen successfully identified a pathway targeted by CirA, 
however we have been unable to successfully detect an interaction between CirA and 
RhoA (mammalian homology of Rho1) or Cdc42 using co-immunoprecipitation 
reactions. This suggests that it may directly interact with another protein in the Rho 
pathway that regulates stress fiber formation To address this hypothesis, we used a 
modified phage display procedure (5). Following RII and RIII of panning, we sequenced 
50 plaques and compared enrichment between rounds. Following RIII, 73% of the 
plaques contained the peptide consensus RRNDLGTE compared to 42% following RII. 
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Figure 3.4 Overexpression of CirA leads to cell rounding and disruption of the actin 
cytoskeleton. (A) Cells overexpressing EGFP-CirA or EGFP alone were scored for 
rounding at 24 hr post-transfection. (B) Stress fibers were visualized by staining with 
Alexa Fluor 555 phalloidin. (A, B) Rounding and stress fiber disruption was determined  
by counting at least 50 transfected cells from triplicate wells. Data are representative of 
at least 3 independent experiments. Statistical analysis were tabulated using t-test and 
generated a statistically difference of P<0.0005. 
A. 
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Figure 3.4 Continued 
B. 
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No other sequences were enriched between RII and RIII. BLAST analysis identified Rho 
GTPase activating protein 29 (RhoGAP 29), also known as PTPL1-associated RhoGAP 
protein 1 (PARG1), as a potential target. These results suggest the mammalian binding 
partner of CirA maybe Rho GAP 29. 
CirA is dispensable for bacterial uptake: Several pathogenic bacteria secrete 
effector proteins that modulate phagocytic uptake (11, 27, 70). However, a recent study 
by Newton et al. (78) suggested the T4SS of C. burnetii is not active until at least 8 hr 
post-infection and requires CCV acidification and endocytic maturation, which 
precludes CirA from being involved in bacterial uptake. To validate this hypothesis, we 
compared uptake of CFSE labelled bacteria by J774Al.1 macrophages. No difference in 
uptake was noted between the strains (Fig. 3.5). These results indicate that CirA does not 
engage Rho GTPases to modulate bacterial uptake. 
Discussion 
 CirA is a T4SS effector that was previously demonstrated to be essential for 
intracellular replication and CCV formation (113). This effector lacks conserved 
domains and is not homologous to other known proteins; however it is highly conserved 
among C. burnetii pathotypes, suggesting it may be important for pathogenesis. In the 
current study we employed a yeast suppressor screen to identify the cellular pathway 
targeted by this effector. Using this approach we identified Rho GTPases as suppressors 
of CirA toxicity.  
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Figure 3.5 CirA is not involved in bacterial uptake. J774A.1 macrophages were infected 
with an MOI of 1 with CFSE labeled bacteria. No difference in uptake was noted 
between the strains. Data are representative of 3 independent experiments with at least 
600 cells from triplicate samples. 
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 Saccharomyces cerevisiae has emerged as a popular model to characterize 
bacterial virulence factors due to the conservation of many pathways between yeast and 
mammals, genetic tractability, and ease of use (104). Heterologous expression of 
bacterial effector proteins in yeast has been exploited in numerous studies to identify 
effectors that impair crucial host processes (4, 18, 100, 113, 114). In an attempt to 
understand the function of these toxic effectors, yeast genetic screens have been 
employed to identify host proteins that when overexpressed, suppress the toxicity of the 
effector protein (35, 100, 108). Principally the lethality associated with L. pneumophila 
AnkX was overcome by overexpression of components involved in membrane 
trafficking and allowed the investigators to determine that it modifies Rab1 by 
phosphorylcholination  (100). This screening tool has since been extended to 
characterize two other effectors: LecE, an effector that manipulates phospholipid 
biosynthesis (108), and Ceg14, an effector that inhibits actin polymerization (35).  
Based on its successful use to characterize 3 Legionella effectors, we employed 
this screening tool to identify the host pathway targeted by CirA. Using this approach we 
demonstrated that the toxicity of CirA could be suppressed by overexpression of 
members of the Rho GTPase family, suggesting this is the pathway targeted by CirA. 
Rho GTPases are targeted by many bacterial effector proteins including Yersinia 
pseudotuberculosis YopE (11), Salmonella typhimurium SopE (30), Vibrio cholerae 
RTX toxin (93), and Escherichia coli EspH (27) indicating this is a conserved 
mechanism among many bacterial pathogens (58). Regulation of Rho activity by 
bacterial effector proteins have been shown to employ 1 of 3 methods (58): 1) Effectors 
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such as YopE, EspM2, and YopO control localization and activation indirectly by 
mimicking Rho GAPs, GEFs, or GDIs, respectively (3, 11). 2)  Regulation can be 
directly through post-translational modification’s including ADP-ribosylation (19), 
adenylation (74), deamidation (59), and glucosylation (102). 3) Lastly, effectors can 
target upstream regulators such as EspH that targets a PH-DH RhoGEF (27) or 
Pasteurella multocida toxin (PMT) that target heterotrimeric G-proteins (82). 
Bioinformatic analysis of CirA did not detect any GAP or GEF domains and it does not 
share homology with bacterial or mammalian GAPs or GEFs. Furthermore co-
immunoprecipitation using RhoA or Cdc42 was unsuccessful in verifying an interaction 
with CirA. Together these results suggest that CirA does not regulate Rho GTPases 
indirectly by mimicking GAPs or GEFs, but instead could post-translationally modify 
the GTPase or act upstream.  
 To determine if CirA binds any proteins directly in a mammalian system, we 
used phage display as an alternative approach to characterize protein-protein 
interactions. Using this approach we identified RhoGAP 29 as a potential binding 
partner for CirA. RhoGAP 29, also known as PARG1, is a GTPase activator that has 
strong activity toward RhoA and weaker activity toward Cdc42 and Rac1 (75, 91). It 
acts in concert with RASIP1 to dampen Rho-associated protein kinase (ROCK) 
signaling. Overexpression of RhoGAP29 in NIH3T3 fibroblast leads to cell rounding, 
detachment, and reduced stress fiber formation (75), a phenotype comparable to cells 
overexpressing CirA. This finding suggests that the disruption of the cytoskeleton 
observed in cells overexpressing CirA, could be due to direct modulation of RhoGAP 29 
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that in turn dampens ROCK signaling through Rho GTPase activation, which ultimately 
resulting in reduced stress fiber formation. Currently we are testing the interaction 
between RhoGAP29 and CirA using co-immunoprecipitation and are also in the process 
of identifying a potential domain required for this interaction. 
 Many pathogenic bacteria target cytoskeletal components including actin, 
intermediate filaments, and microtubules to modulate invasion, establish a replicative 
niche, facilitate cell-to-cell spread through actin based motility, and disseminate (38). 
Specifically, several pathogens secrete T3S effectors that target Rho GTPases to 
modulate uptake. Salmonella releases at least 4 effector proteins to modulate actin 
rearrangements through Rho GTPases: SopE and SopE2 directly activate by mimicking 
Rho GEFs (42, 98), whereas SopB indirectly activates Rho GTPases through inositol  
phosphatase (103). Following actin polymerization, SptP down-regulates cytoskeletal 
rearrangements induced by other T3S effectors by acting as a Rac1 and Cdc42 GAP. 
This tightly balanced cycle acts to rebuild the cytoskeleton following invasion (30). In 
contrast to the model exemplified by Salmonella, Yersina secretes an array of 
antiphagocytic T3S effectors that disrupts the cytoskeleton to block uptake, most notable 
is YopE  which targets RhoA, Rac1, and Cdc42 by mimicking Rho GAPs (11). While 
targeting of Rho GTPase to modulate uptake is a common theme among secreted 
effectors, it is unlikely to be the reason C. burnetii CirA targets this pathway. Similarly, 
it is that CirA co-opts cytoskeletal components for actin based motility to do its vacuolar 
localization and no defect in dissemination was noted for this mutant, suggesting CirA is 
not necessary for release from the host cell. Instead we propose that CirA is secreted by 
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the T4SS system after uptake, where it indirectly modulates RhoGTPases by engaging 
RhoGAP29 to regulate the size of the CCV (Fig. 3.6). 
 
 
 
Figure 3.6 CirA’s interaction with RhoGAPs is necessary to promote the formation of a 
spacious CCV. In the current study we demonstrate that CirA is a T4SS that is necessary 
for intracellular replication and for formation of the characteristically spacious CCV. 
Following endocytic maturation, CirA is secreted and interacts with RhoGAPs 29 and 
33. 
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CHAPTER IV 
CONCLUSIONS 
 Like many intracellular pathogens, Coxiella burnetii encodes a specialized 
secretion system that translocates numerous effector proteins into the host cell 
cytoplasm. In the current study, we used an enhanced bioinformatics screen to identify 
candidate substrates, which resulted in the identification of 85 novel secretion substrates 
(20, 113). Preliminary characterization of these substrates using large scale screens 
revealed these substrates traffic to distinct subcellular compartments; interfere with 
crucial host cell processes, and play an integral role in intracellular replication and CCV 
formation.  
 Many intracellular pathogens secrete effector proteins that traffic to the nucleus 
where they modify chromatin and modulate the transcriptional response. Post-
translational modification of histones by SET domain containing methyltranferases L. 
pneumophila RomA and C. trachomatis Nue has been shown to play an crucial role in 
modulating the inflammatory response by direct histone methylation (85, 87). H. pylori 
also affects histone modifications by decreasing histone phosphorylation and acetylation 
in a cagPAI-dependent mechanism (26). AnkA, a secreted effector from Anaplasma 
phagocytophilum, binds to the CYBB promoter resulting in decreased H3 acetylation and 
CYBB expression, which ultimately leads to decreased oxidative burst (31, 32, 84). 
Expression of C. burnetii secretion substrates as C-terminal fusions to EGFP identified 
six substrates that traffic to the nucleus (20, 113). Bioinformatic analysis of these 
substrates revealed the presence of a nuclear localization signal (NLS), as evident by 
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arginine and lysine enrichment, in five of the secretion substrates (Cbu0388, Cbu1314, 
Cbu1524, Cbu0393, and Cbu0794). The finding that these substrates possess an NLS 
suggests that these substrates have the necessary information to enter the nucleus and 
likely function in the nucleus in C. burnetii infected cells (Fig. 4.1). Further analysis of 
these nuclear substrates revealed two substrates, Cbu1314 and Cbu0388, encode DNA 
binding domains. Furthermore, Cbu0388 possesses a C(X)5R motif, suggesting it maybe 
a phosphatase. The fact that many intracellular pathogens secrete effectors that modify 
histones coupled with ectopic localization, the presence of an NLS, DNA binding 
domain, and phosphatase domain suggests this effector may dephosphorylate histones. 
Current study is underway to determine if either Cbu1314 or Cbu0388 associate with 
host chromatin using ChIP-seq. 
 Infection of a host cell by C. burnetii leads to the formation of a spacious vacuole 
that surprisingly doesn’t affect host viability, suggesting C. burnetii actively promotes 
host cell viability by the secretion of anti-apoptotic effectors. In a screen to identify anti-
apoptotic proteins, three T4SS effectors; AnkG, CaeA, and CaeB were shown to block 
staurosporin apoptosis. AnkG inhibits apoptosis by binding pro-apoptotic gC1qR (p32) 
(60). CaeB was also found to inhibit the intrinsic apoptosis at the mitochondrial level in 
a pathway that does not require binding to p32, whereas the mechanism of CaeA 
inhibition of apoptosis is less clear (52). Ectopic expression and bioinformatics analysis 
of CaeA suggest it localizes to the nucleus (18, 20, 52, 113). It will be interesting to 
determine if modulation of apoptosis by this effector involves up-regulation of anti-
apoptotic or down-regulation of pro-apoptotic factors caused by histone modifications. 
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 While promoting host cell viability is of paramount importance to pathogen 
survival, the fusogenicity of the CCV is also critical for an effective infection. The use of 
a variety of inhibitors and overexpression constructs have demonstrated that the C. 
burnetii CCV interacts with vesicular pathways including endocytic (Rab5, Rab7), 
autophagic (LC3), and secretory (Rab1) (17, 36, 88, 107). Fusogenicity with these 
compartments is mediated by recruitment of N- ethylmaleimide-sensitive factor 
attachment protein receptors (SNARE) and importantly depletion of either Vamp7 and 
syntaxin-17 results in aberrant vacuole formation (16, 68). While interactions with many 
of these compartments require active protein synthesis and suggest these interactions 
could be mediated by secreted effector proteins, the identity of these effector proteins 
remains largely unknown. Recently the characterization of one effector, CvpA, 
demonstrated that this effector co-ops clathrin transport mechanisms in order to acquire 
endolysosomal membrane. Deletion of cvpA or inhibition of clathrin or AP2 lead to 
decreased intracellular replication and CCV formation, highlighting the importance of 
this pathway in normal development.  
 In the current study we identified and preliminarily characterized a T4SS 
effector, CirA, that when overexpressed, resulted in cell rounding, cell detachment, and 
disruption of the actin cytoskeleton through indirect modulation of Rho GTPases. Unlike 
other bacterial effector proteins that target Rho GTPases to modulate uptake, CirA is 
unique in that it is dispensable for uptake. Our results suggest that CirA may be involved 
in regulating size and formation of the spacious CCV as both F-actin and Rho GTPases 
are recruited to the CCV and are crucial for normal development (1). Studies have 
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shown that F-actin assembles on phagosomes, which serves as “tracks” on which 
lysosomes or late endosomes can progress to facilitate fusions with phagosomes (1, 50). 
This suggests that recruitment of both F-actin and Rho GTPases may facilitate 
heterotypic fusions with endosomes and lysosomes as well as homotypic fusions with 
other small CCVs and serve as a method for delivering membrane to the growing 
vacuole (1). 
 In addition to a crucial role for Rho GTPases in vacuole development, it is likely 
that other GTPases from the Ras superfamily could play an important role in facilitating 
interactions with other cellular compartments. This is exemplified by L. pneumophila 
which is a master manipulator of Rab function. Rab1, a GTPase that regulates protein 
transport from the endoplasmic reticulum to the golgi, is recruited to the Legionella-
containing vacuole (LCV) by the Rab GEF DrrA/SidM (74). After two hours, Rab1 
begins to dissociate from the LCV due to inactivation by the Rab GAP LepB (49). Rab1 
activity is also tightly regulated by AMPylation by DrrA (72) and phosphocholination by 
AnkX (100). Post-translational modification of DrrA by these two effectors inhibits the 
activity of LepB and enhances accumulation on the LCV (41). These post-translational 
modifications are reversed by SidD that deadenylylates Rab1 (100) and Lem3 that is a 
dephosphocholinase (100). While Coxiella and Legionella replicate in distinct 
intracellular compartments, Rab1 is recruited to the CCV in a process dependent on 
active protein synthesis, suggesting an effector mediated event and is likely that it 
encodes effectors similar to those found in Legionella for Rab1 manipulation (17) 
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 Ubiquitination is a reversible post-translational modification that is involved in 
protein degradation, signal transduction, host defense, and membrane trafficking (22). 
While bacteria do not encode ubiquitin (97), numerous bacteria pathogens including 
Listeria monocytogenes, Salmonella typhimurium, Yersinia sp, and Legionella 
pneumophila have evolved sophisticated mechanisms for subverting host ubiquitin for 
their own benefit. Coxiella burnetii encodes three T4SS substrates (Cbu1217, Cbu0814, 
and CbuA0014) with F-boxes, a eukaryotic domain that serves as a scaffold for the 
formation of a functional Skp-Cullin-F-box E3 ubiquitin ligase complex (28). Two 
Legionella F-box containing effectors, LegU1 and LegAU13, direct the ubiquitination of 
the host protein BAT3, which may reduce the ER stress response and inhibit apoptosis 
(28). Bacteria also use ubiquitination to modulate the host innate immune system. 
Yersina spp. employ the de-ubiquitination effectors YopJ/P to de-ubiquination of 
TRAF6. In contrast to targeting host proteins, the host ubiquitination pathway can be 
employed to regulate the activity of its own effectors. Ubiquitination of SopB serves to 
control the subcellular localization of this effector, in that prior to ubiquitination, SopB 
localizes to the plasma membrane, but then it is quickly mono-ubiquitinated causing it to 
associate with the Salmonella containing vacuole (SCV). Once associated with the SCV, 
SopB directs remodeling of the phagosome by recruiting high levels of 
phosphatidylinositol-3-phosphate (PI(3)P), which subverts the normal phagosome 
trafficking and inhibits lysosome fusion and acidification (22).  LubX, a functional E3 
ligase of L. pneumophia, regulates the activity of another Legionella T4SS effector, 
SidH, by ubquitinating it, thus targeting it for proteosomal degradation (55).   
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 Autophagy plays an integral role in maintaining the quality of cellular 
components by delivering cytoplasmic proteins or damaged organelles to the lysosomes 
for degradation. Many pathogenic bacteria  have evolved sophisticated mechanisms for 
inhibiting autophagic initiation, avoiding autophagic capture, suppressing maturation of 
the autolysosome, or for utilizing host autophagy (24). While it was originally believed 
that autophagy was detrimental to intracellular pathogens, it is now known that 
autophagic activation benefits some bacterial pathogens including C. burnetii, L. 
pneumophila, A. phagocytophilum and Brucella abortus by serving as a nutrient source, 
providing a replication niche that protects them from the endolysosomal pathway or by 
direct use of autophagic machinery (25). Within minutes of uptake, the CCV is 
decorated with LC3, indicating an interaction with the autophagic pathway (88, 107). 
The CCV also recruits Beclin1, which when overexpressed, delays the arrival of the 
lysosome, enhances bacterial replication and increases the number of infected cells. 
(107). Beclin1 has a BH3 domain that interacts with anti-apoptotic proteins such as Bcl-
2 (24). Interaction between these two proteins and subsequent recruitment to the PV is 
intriguing given that interaction between Bcl-2 and Beclin1 has been demonstrated to 
dampen autophagy. Thus, co-recruitment of both may be a pathogenic mechanism to 
prevent excess autophagy that could lead to autophagic cell death (24, 25). LC3 
recruitment to the PV occurs within minutes of uptake, so it is unlikely that the initial 
engagement of the autophagy pathway is dependent on a T4SS effector. However, a 
recent study by Voth et al. (109) identified a T4SS substrate, CpeB, that when 
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ectopically expressed co-localizes with LC3, which suggest that the T4SS does play a 
role in autophagy, possibly at later time points of infection cycle.  
 Host pathogen interactions are very complex, intricate proceses that require 
modulation and manipulation of numerous pathways. Many pathogens have evolved 
sophisticated methods for facilitating subversion; principle among them is secretion of 
effector proteins. To date over 100 secreted substrates of C. burnetii T4SS have been 
identified, representing approximately 5% of its proteome.  As the field continues to 
advance and more genetic tools are developed, understanding the role of these proteins 
in pathogenesis will be of paramount importance. 
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Figure 4.1 Role of C. burnetii T4SS substrates in intracellular infection. Through a 
bacterial two-hybrid, bioinformatics, and genomic screens, over 100 C. burnetii T4SS 
substrates have been identified. Large-scale screens have identified 6 substrates 
(Cbu1314, Cbu0388, Cbu0129, Cbu1524, Cbu0794, and Cbu0393) that traffic to the 
nucleus and may play a role in transcriptional modulation. One effector, CvpA, was 
recently shown to associate with host clathrin and may serve as a source of membrane 
for the growing CCV. An additional effector, CirA, localizes to the plasma membrane 
and reduces stress fiber formation when overexpressed, possibly by interacting with 
RhoGAP 33. Three effectors (AnkG, CaeA, and CaeB) are capable of blocking 
exogenously stimulated apoptosis. An additional 3 effectors (CbuA0014, Cbu1217, and 
Cbu0814) possess an F-box motif and may mediate proteasomal degradation of host 
proteins. A plasmid encoded effector, CpeB, co-localizes with the autophagosomal 
marker LC3. 
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